<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis - Kew, KM - 2014 | Cochrane Library</title> <meta content="Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis - Kew, KM - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010844.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis - Kew, KM - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010844.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010844.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis" name="citation_title"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="kkew@sgul.ac.uk" name="citation_author_email"/> <meta content="Sofia Dias" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Christopher J Cates" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD010844.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/03/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010844.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010844.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010844.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [therapeutic use]; Adrenergic beta‐2 Receptor Agonists [therapeutic use]; Cholinergic Antagonists [therapeutic use]; DNA‐Binding Proteins; Delayed‐Action Preparations [administration &amp; dosage]; Muscarinic Antagonists [therapeutic use]; Nuclear Proteins; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Randomized Controlled Trials as Topic; Transcription Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010844.pub2&amp;doi=10.1002/14651858.CD010844.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010844\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010844\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010844.pub2",title:"Long\\u2010acting inhaled therapy (beta\\u2010agonists, anticholinergics and steroids) for COPD: a network meta\\u2010analysis",firstPublishedDate:"Mar 26, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010844.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010844.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010844.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010844.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010844.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010844.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010844.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010844.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010844.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010844.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6072 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010844.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/appendices#CD010844-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information#CD010844-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information#CD010844-cr-0003">Sofia Dias</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information#CD010844-cr-0004">Christopher J Cates</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information/en#CD010844-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 March 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010844.pub2">https://doi.org/10.1002/14651858.CD010844.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010844-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010844-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010844-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010844-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010844-abs-0001" lang="en"> <section id="CD010844-sec-0001"> <h3 class="title" id="CD010844-sec-0001">Background</h3> <p>Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving quality of life and preventing or treating exacerbations. </p> <p>Treatment tends to begin with one inhaler, and additional therapies are introduced as necessary. For persistent or worsening symptoms, long‐acting inhaled therapies taken once or twice daily are preferred over short‐acting inhalers. Several Cochrane reviews have looked at the risks and benefits of specific long‐acting inhaled therapies compared with placebo or other treatments. However for patients and clinicians, it is important to understand the merits of these treatments relative to each other, and whether a particular class of inhaled therapies is more beneficial than the others. </p> </section> <section id="CD010844-sec-0002"> <h3 class="title" id="CD010844-sec-0002">Objectives</h3> <p>To assess the efficacy of treatment options for patients whose chronic obstructive pulmonary disease cannot be controlled by short‐acting therapies alone. The review will not look at combination therapies usually considered later in the course of the disease. </p> <p>As part of this network meta‐analysis, we will address the following issues.</p> <p>1. How does long‐term efficacy compare between different pharmacological treatments for COPD?<br/> 2. Are there limitations in the current evidence base that may compromise the conclusions drawn by this network meta‐analysis? If so, what are the implications for future research? </p> </section> <section id="CD010844-sec-0003"> <h3 class="title" id="CD010844-sec-0003">Search methods</h3> <p>We identified randomised controlled trials (RCTs) in existing Cochrane reviews by searching the Cochrane Database of Systematic Reviews (CDSR). In addition, we ran a comprehensive citation search on the Cochrane Airways Group Register of trials (CAGR) and checked manufacturer websites and reference lists of other reviews. The most recent searches were conducted in September 2013. </p> </section> <section id="CD010844-sec-0004"> <h3 class="title" id="CD010844-sec-0004">Selection criteria</h3> <p>We included parallel‐group RCTs of at least 6 months' duration recruiting people with COPD. Studies were included if they compared any of the following treatments versus any other: long‐acting beta<sub>2</sub>‐agonists (LABAs; formoterol, indacaterol, salmeterol); long‐acting muscarinic antagonists (LAMAs; aclidinium, glycopyrronium, tiotropium); inhaled corticosteroids (ICSs; budesonide, fluticasone, mometasone); combination long‐acting beta<sub>2</sub>‐agonist (LABA) and inhaled corticosteroid (LABA/ICS) (formoterol/budesonide, formoterol/mometasone, salmeterol/fluticasone); and placebo. </p> </section> <section id="CD010844-sec-0005"> <h3 class="title" id="CD010844-sec-0005">Data collection and analysis</h3> <p>We conducted a network meta‐analysis using Markov chain Monte Carlo methods for two efficacy outcomes: St George's Respiratory Questionnaire (SGRQ) total score and trough forced expiratory volume in one second (FEV<sub>1</sub>). We modelled the relative effectiveness of any two treatments as a function of each treatment relative to the reference treatment (placebo). We assumed that treatment effects were similar within treatment classes (LAMA, LABA, ICS, LABA/ICS). We present estimates of class effects, variability between treatments within each class and individual treatment effects compared with every other. </p> <p>To justify the analyses, we assessed the trials for clinical and methodological transitivity across comparisons. We tested the robustness of our analyses by performing sensitivity analyses for lack of blinding and by considering six‐ and 12‐month data separately. </p> </section> <section id="CD010844-sec-0006"> <h3 class="title" id="CD010844-sec-0006">Main results</h3> <p>We identified 71 RCTs randomly assigning 73,062 people with COPD to 184 treatment arms of interest. Trials were similar with regards to methodology, inclusion and exclusion criteria and key baseline characteristics. Participants were more often male, aged in their mid sixties, with FEV<sub>1</sub> predicted normal between 40% and 50% and with substantial smoking histories (40+ pack‐years). The risk of bias was generally low, although missing information made it hard to judge risk of selection bias and selective outcome reporting. Fixed effects were used for SGRQ analyses, and random effects for Trough FEV<sub>1</sub> analyses, based on model fit statistics and deviance information criteria (DIC). </p> <p><b>SGRQ</b> <br/> SGRQ data were available in 42 studies (n = 54,613). At six months, 39 pairwise comparisons were made between 18 treatments in 25 studies (n = 27,024). Combination LABA/ICS was the highest ranked intervention, with a mean improvement over placebo of ‐3.89 units at six months (95% credible interval (CrI) ‐4.70 to ‐2.97) and ‐3.60 at 12 months (95% CrI ‐4.63 to ‐2.34). LAMAs and LABAs were ranked second and third at six months, with mean differences of ‐2.63 (95% CrI ‐3.53 to ‐1.97) and ‐2.29 (95% CrI ‐3.18 to ‐1.53), respectively. Inhaled corticosteroids were ranked fourth (MD ‐2.00, 95% CrI ‐3.06 to ‐0.87). Class differences between LABA, LAMA and ICS were less prominent at 12 months. Indacaterol and aclidinium were ranked somewhat higher than other members of their classes, and formoterol 12 mcg, budesonide 400 mcg and formoterol/mometasone combination were ranked lower within their classes. There was considerable overlap in credible intervals and rankings for both classes and individual treatments. </p> <p><b>Trough FEV<sub>1</sub> </b> <br/> Trough FEV<sub>1</sub> data were available in 46 studies (n = 47,409). At six months, 41 pairwise comparisons were made between 20 treatments in 31 studies (n = 29,271). As for SGRQ, combination LABA/ICS was the highest ranked class, with a mean improvement over placebo of 133.3 mL at six months (95% CrI 100.6 to 164.0) and slightly less at 12 months (mean difference (MD) 100, 95% CrI 55.5 to 140.1). LAMAs (MD 103.5, 95% CrI 81.8 to 124.9) and LABAs (MD 99.4, 95% CrI 72.0 to 127.8) showed roughly equivalent results at six months, and ICSs were the fourth ranked class (MD 65.4, 95% CrI 33.1 to 96.9). As with SGRQ, initial differences between classes were not so prominent at 12 months. Indacaterol and salmeterol/fluticasone were ranked slightly better than others in their class, and formoterol 12, aclidinium, budesonide and formoterol/budesonide combination were ranked lower within their classes. All credible intervals for individual rankings were wide. </p> </section> <section id="CD010844-sec-0007"> <h3 class="title" id="CD010844-sec-0007">Authors' conclusions</h3> <p>This network meta‐analysis compares four different classes of long‐acting inhalers for people with COPD who need more than short‐acting bronchodilators. Quality of life and lung function were improved most on combination inhalers (LABA and ICS) and least on ICS alone at 6 and at 12 months. Overall LAMA and LABA inhalers had similar effects, particularly at 12 months. The network has demonstrated the benefit of ICS when added to LABA for these outcomes in participants who largely had an FEV<sub>1</sub> that was less than 50% predicted, but the additional expense of combination inhalers and any potential for increased adverse events (which has been established by other reviews) require consideration. Our findings are in keeping with current National Institute for Health and Care Excellence (NICE) guidelines. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010844-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010844-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010844-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010844-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010844-abs-0005" lang="en"> <h3>Which long‐acting inhaled drugs, used alone or in combination, are the most effective for people with COPD? </h3> <p><b>Why is this question important?</b> </p> <p>Inhaled drugs for COPD have been shown to relieve symptoms, improve quality of life and prevent or treat flare‐ups. Treatment with these inhaled drugs tends to begin with one inhaler, and additional therapies are introduced as necessary. For persistent or worsening symptoms, long‐acting inhaled drugs taken once or twice daily are preferred over short‐acting ones. Several Cochrane reviews have looked at the risks and benefits of specific long‐acting inhaled therapies compared with placebo or other treatments. However for patients and clinicians, it is important to understand the benefits of these treatments relative to each other, and whether a particular type of inhaled therapy is more beneficial than the others. </p> <p><b>How did we answer the question?</b> <br/> We looked for studies in existing Cochrane reviews and performed detailed electronic searches up to September 2013. Studies were included if they lasted at least six months and compared any of the following treatments versus any other for people with COPD: long‐acting beta<sub>2</sub>‐agonists (LABAs—formoterol, indacaterol, salmeterol); long‐acting muscarinic antagonists (LAMAs—aclidinium, glycopyrronium, tiotropium); inhaled corticosteroids (ICSs—budesonide, fluticasone, mometasone); combination long‐acting beta<sub>2</sub>‐agonist and inhaled corticosteroid (LABA/ICS—formoterol/budesonide, formoterol/mometasone, salmeterol/fluticasone); and placebo. </p> <p>We conducted a network meta‐analysis to assess the benefits of each type of treatment (e.g. long‐acting beta<sub>2</sub>‐agonists) relative to the others for quality of life and lung function. We also looked at how much individual treatments varied (e.g. How different were the three inhaled steroids from one other?) and whether particular treatments were more effective than others. We assessed the data for six months and 12 months separately and reported six months as the primary findings. </p> <p><b>What did we find?</b> <br/> We found 71 relevant studies, but not all measured the outcomes we were interested in. Forty‐two studies were included in the quality of life analyses (measured on St George's Respiratory Questionnaire), and 46 were included in the lung function analyses. </p> <p>Evidence from good quality and similar trials supported LABA/ICS combinations as the most likely treatment strategy to bring the greatest improvement to quality of life and lung function. Combination therapy gave an average benefit of 3.9 units over placebo at six months. LAMAs and LABAs were ranked second and third at six months (‐2.63 and ‐2.29 units, respectively), especially when unreliable trials were not included, but a large degree of overlap in the estimates was noted. </p> <p>Combination LABA/ICS was the highest ranked class for trough forced expiratory volume in one second (FEV<sub>1</sub>), with mean improvement over placebo of 133 mL at six months (95% credible Interval (CrI) 101 to 164). As was the case for SGRQ, LAMAs (mean difference (MD) 104, 95% CrI 82 to 125) were ranked just ahead of LABAs (MD 99, 95% CrI 72 to 128) at six months, and ICSs were the lowest ranked class (MD 65, 95% CrI 33 to 97). </p> <p>For both outcomes, the effects of LABA and ICS used alone appeared to increase when used together for six months, but initial differences between the treatment classes were less obvious after a year of treatment. </p> <p><b>Conclusion</b> <br/> Quality of life and lung function were improved most on combination inhalers (LABA and ICS) and least on ICS alone at 6 and 12 months. Overall LAMA and LABA inhalers had similar effects, particularly at 12 months. The network has demonstrated the benefit of ICS when added to LABA for these outcomes in participants who largely had an FEV<sub>1</sub> that was less than 50% predicted, but the additional expense of combination inhalers and any potential for increased adverse events (which has been shown by other reviews) require consideration. Our findings are in keeping with current National Institute for Health and Care Excellence (NICE) guidelines. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010844-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-sec-0112">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-sec-0162">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010844-sec-0112"></div> <h3 class="title" id="CD010844-sec-0113">Implications for practice</h3> <section id="CD010844-sec-0113"> <p>This network meta‐analysis compares three different classes of long‐acting inhalers for people with COPD who need more than short‐acting bronchodilators. Quality of life and lung function were improved most on combination inhalers (LABA and ICS) and least on ICS alone at 6 and at 12 months. Overall LAMA and LABA inhalers had similar effects, particularly at 12 months. The network has demonstrated the benefit of ICS when added to LABA for these outcomes in participants who largely had an FEV<sub>1</sub> that was less than 50% predicted, but the additional expense of combination inhalers and any potential for increased adverse events (which has been established by other reviews) require consideration. Our findings are in keeping with current NICE guidelines. </p> </section> <h3 class="title" id="CD010844-sec-0114">Implications for research</h3> <section id="CD010844-sec-0114"> <p>Studies assessing emerging treatments in head‐to‐head trials with older members of their class would be particularly useful for assessing relative efficacy. When including active treatment controls, studies should deliver all treatments in a double‐blind fashion to minimise performance and detection bias for all comparisons. As more studies are conducted and published for emerging LABAs, LAMAs, ICSs and LABA/ICS combinations, widening the scope of the network might increase the usefulness of this review. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010844-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-sec-0139">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD010844-sec-0029"></div> <section id="CD010844-sec-0030"> <h3 class="title" id="CD010844-sec-0030">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterised by chronic and progressive breathlessness, cough, sputum production and airflow obstruction, all of which lead to restricted activity and poor quality of life (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). The World Health Organization (<a href="./references#CD010844-bbs2-0195" title="World Health Organization. Chronic respiratory diseases. http://www.who.int/respiratory/en/ (accessed 3 October 2013). ">WHO</a>) has estimated that COPD is the fourth or fifth most common single cause of death worldwide, and the treatment and management costs present a significant burden to public health. In the UK, the annual cost of COPD to the National Health Service (NHS) is estimated to be £1.3 million per 100,000 people (<a href="./references#CD010844-bbs2-0183" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 3 October 2013). ">NICE 2011</a>). Furthermore, because of slow onset and under‐recognition of the disease, it is heavily under‐diagnosed (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). COPD comprises a combination of bronchitis and emphysema and involves chronic inflammation and structural changes in the lung. Cigarette smoking is the most important risk factor; however, air pollution and occupational dust and chemicals can also increase the risk of developing the disease. COPD is a progressive disease that leads to decreased lung function over time, even with the best available care. Currently no cure for COPD is known, although it is both preventable and treatable. Management of the disease is multifaceted and includes interventions for smoking cessation (<a href="./references#CD010844-bbs2-0193" title="van derMeer ReginaM , WagenaE , Ostelo RaymondWJG , Jacobs AnneliesJE , vanSchayckO . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD002999] ">van der Meer 2001</a>), pharmacological treatments (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>), education (<a href="./references#CD010844-bbs2-0163" title="EffingT , Monninkhof EvelynEM , van derValk PaulPDLPM , Zielhuis GerhardGA , WaltersEH , van derPalen JobJ , et al. Self‐management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002990] ">Effing 2007</a>) and pulmonary rehabilitation (<a href="./references#CD010844-bbs2-0176" title="LacasseY , GoldsteinR , Lasserson TobyJ , MartinS . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003793] ">Lacasse 2006</a>; <a href="./references#CD010844-bbs2-0185" title="PuhanMA , Gimeno‐SantosE , ScharplatzM , TroostersT , WaltersEH , SteurerJ . Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD005305] ">Puhan 2011</a>). Pharmacological therapy is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function and preventing and treating exacerbations. COPD exacerbations impair patients' quality of life (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>), and a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in use of acute care services or hospitalisation (<a href="./references#CD010844-bbs2-0169" title="HutchinsonA , BrandC , IrvingL , RobertsC , ThompsonP , CampbellD . Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal2010;40(5):364‐71. ">Hutchinson 2010</a>). In the UK, one in eight emergency admissions to hospital is for COPD, and it is one of the most costly conditions treated by the NHS (<a href="./references#CD010844-bbs2-0183" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 3 October 2013). ">NICE 2011</a>). Appropriate pharmacological management of the disease is therefore important, particularly for reducing and preventing exacerbations. </p> <section id="CD010844-sec-0031"> <h4 class="title">Description of the interventions</h4> <p>Pharmacological management of COPD tends to begin with one treatment, and additional therapies are introduced as necessary to control symptoms and reduce the frequency and severity of exacerbations (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). The first step is often a short‐acting bronchodilator for control of breathlessness when needed: either a short‐acting beta<sub>2</sub>‐agonist (SABA; e.g. salbutamol) or the short‐acting muscarinic antagonist (SAMA) ipratropium. Both bronchodilators have a duration of action of four to six hours (<a href="./references#CD010844-bbs2-0148" title='BeehKM , BeierJ . The short, the long, and the "ultra‐long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy2010;27(3):150‐9. '>Beeh 2010</a>), and they improve lung function and breathlessness (<a href="./references#CD010844-bbs2-0145" title="AppletonS , JonesT , PooleP , PilottoL , AdamsR , Lasserson TobyJ , et al. Ipratropium bromide versus short acting beta‐2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD001387] ">Appleton 2006</a>; <a href="./references#CD010844-bbs2-0188" title="SestiniP , RenzoniE , RobinsonS , PooleP , RamFSF . Short‐acting beta2‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD001495] ">Sestini 2009</a>). For persistent or worsening breathlessness associated with lung function decline, long‐acting bronchodilators may be introduced (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). These comprise long‐acting beta<sub>2</sub>‐agonists, such as salmeterol or formoterol (LABAs; duration of action 12 hours) and indacaterol (duration of action 24 hours), and long‐acting anticholinergic agents, such as tiotropium (duration of action 24 hours) and more recently aclidinium bromide and glycopyrronium bromide. Regular treatment with long‐acting bronchodilators is preferred over treatment with regular short‐acting bronchodilators on the basis of efficacy and adverse effects (<a href="./references#CD010844-bbs2-0148" title='BeehKM , BeierJ . The short, the long, and the "ultra‐long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy2010;27(3):150‐9. '>Beeh 2010</a>; <a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). An alternative when bronchodilators are not available or affordable is theophylline, an oral phosphodiesterase (PDE) inhibitor. However, theophylline is less effective and is less well tolerated than inhaled long‐acting bronchodilators. For patients with severe or very severe COPD (forced expiratory volume in one second (FEV<sub>1</sub>) &lt; 50% predicted) with repeated exacerbations, <a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a> recommends the addition of inhaled corticosteroids (ICSs) to bronchodilator treatment. ICSs are anti‐inflammatory drugs that are licensed as combination inhalers with LABAs. The most common combinations of ICS and LABA in combination inhalers are fluticasone and salmeterol, and budesonide and formoterol. The most severely ill group of patients with advanced COPD may also benefit from treatment with the PDE<sub>4</sub> inhibitor roflumilast, which may reduce the risk of exacerbations (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>), alongside other beta<sub>2</sub>‐agonists or anticholinergic agents and ICS, but these combinations are not considered in this review. </p> </section> <section id="CD010844-sec-0032"> <h4 class="title">How the interventions might work</h4> <section id="CD010844-sec-0033"> <h5 class="title">Long‐acting beta<sub>2</sub>‐agonists </h5> <p>Inhaled long‐acting beta<sub>2</sub>‐agonists (LABAs) activate beta<sub>2</sub>‐receptors in the smooth muscle of the airway, leading to a cascade of reactions that result in bronchodilation. Commonly used LABAs include salmeterol, formoterol and indacaterol. The duration of action for salmeterol and formoterol is approximately 12 hours; therefore they are usually taken twice daily. Indacaterol has a duration of action of 24 hours and therefore can be taken once daily. As with long‐acting muscarinic antagonists (LAMAs), LABAs are commonly used to control symptoms and reduce exacerbations in stable COPD (<a href="./references#CD010844-bbs2-0179" title="MoenMD . Indacaterol: in chronic obstructive pulmonary disease. Drugs2010;70(17):2269‐80. ">Moen 2010</a>; <a href="./references#CD010844-bbs2-0186" title="RodrigoGJ , NanniniLJ , Rodríguez‐RoisinR . Safety of long‐acting β‐agonists in stable COPD: a systematic review. Chest2008;133(5):1079‐87. ">Rodrigo 2008</a>). Possible side effects of LABAs include cardiac effects such as arrhythmia and palpitations, muscle tremors, headache and dry mouth (<a href="./references#CD010844-bbs2-0149" title="BergerWE , NadelJA . Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2008;102(2):173‐88. ">Berger 2008</a>). </p> </section> <section id="CD010844-sec-0034"> <h5 class="title">Inhaled corticosteroids</h5> <p>Inhaled corticosteroids (ICSs) are anti‐inflammatory drugs. ICSs are licensed as combination inhalers with LABA. The most common combinations of ICS and LABA in combination inhalers are fluticasone and salmeterol, and budesonide and formoterol. Combination inhalers have similar effects to LABA alone, reducing exacerbation rates and improving patients' quality of life. However, some have argued that the difference is small (<a href="./references#CD010844-bbs2-0187" title="RodrigoGJ , Castro‐RodriguezJA , PlazaV . Safety and efficacy of combined long‐acting beta‐agonists and inhaled corticosteroids vs long‐acting beta‐agonists monotherapy for stable COPD: a systematic review. Chest2009;136(4):1029‐38. ">Rodrigo 2009</a>), and ICS therapy, alone or in combination with beta<sub>2</sub>‐agonists, is associated with increased risk of pneumonia and osteoporotic fracture (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>; <a href="./references#CD010844-bbs2-0177" title="LokeYK , CavallazziR , SinghS . Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta‐analysis of randomised controlled trials and observational studies. Thorax2011;66(8):699‐708. ">Loke 2011</a>; <a href="./references#CD010844-bbs2-0189" title="SinghS , LokeYK . An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2010;5:189‐95. ">Singh 2010</a>). </p> </section> <section id="CD010844-sec-0035"> <h5 class="title">Long‐acting muscarinic antagonists</h5> <p>Long‐acting muscarinic antagonists (LAMAs) are anticholinergic agents that block the action of the neurotransmitter acetylcholine. The LAMA tiotropium has gained widespread acceptance as once‐daily maintenance therapy in stable COPD for its effects on symptoms and exacerbations (<a href="./references#CD010844-bbs2-0147" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876] ">Barr 2005</a>; <a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). Two newer LAMAs that can be taken once daily—aclidinium bromide and glycopyrronium bromide—have recently been licensed for the maintenance treatment of people with COPD. Anticholinergic adverse effects that may occur include dry mouth, constipation and tachycardia (<a href="./references#CD010844-bbs2-0192" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. ">Tashkin 2008</a>). </p> </section> </section> </section> <section id="CD010844-sec-0036"> <h3 class="title" id="CD010844-sec-0036">Why it is important to do this review</h3> <p>Several systematic reviews have looked at the risks and benefits of specific inhaled therapies compared with placebo or other inhaled therapies. However for patients or for clinicians facing patients, the question is often this: Which of the long‐acting therapy options is the most beneficial treatment option for patients no longer obtaining symptom relief from short‐acting therapies, but for whom PDE<sub>4</sub> inhibitors or other additional therapies are not yet necessary? Two recent network meta‐analyses have focused primarily on safety outcomes (<a href="./references#CD010844-bbs2-0157" title="DecramerML , HananiaNA , Lotvall , JO , YawnBP . The safety of long‐acting β2‐agonistsin the treatment of stable chronic obstructive pulmonary disease. International Journal of COPD2013;8:53‐64. ">Decramer 2013</a>; <a href="./references#CD010844-bbs2-0161" title="DongY , LinH , ShauW , WuY , ChangC , LaiM . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68:48‐56. ">Dong 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010844-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-sec-0147">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010844-sec-0037"></div> <p>To assess the efficacy of treatment options for patients whose chronic obstructive pulmonary disease cannot be controlled by short‐acting therapies alone. The review will not look at combination therapies usually considered later in the course of the disease. </p> <p>As part of this network meta‐analysis, we will address the following issues:</p> <p> <ol id="CD010844-list-0001"> <li> <p>How does long‐term efficacy compare between different pharmacological treatments for COPD? </p> </li> <li> <p>Are there limitations in the current evidence base that may compromise the conclusions drawn by this network meta‐analysis? If so, what are the implications for future research? </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010844-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-sec-0038">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-sec-0148">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010844-sec-0038"></div> <section id="CD010844-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010844-sec-0040"> <h4 class="title">Types of studies</h4> <p>We included randomised control trials (RCTs) with a parallel‐group design of at least 24 weeks' duration. Cross‐over trials were not included, as the pharmaceutical treatments under study can have long‐acting effects. </p> </section> <section id="CD010844-sec-0041"> <h4 class="title">Types of participants</h4> <p>We included RCTs that recruited participants with a clinical diagnosis of COPD, such as <a href="./references#CD010844-bbs2-0146" title="CelliBR , MacNeeW . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal2004;23(6):932‐46. ">ATS/ERS 2004</a>. We looked for the following inclusion criteria. </p> <p> <ol id="CD010844-list-0002"> <li> <p>Forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio &lt; 0.7, which confirms the presence of persistent airflow limitation. </p> </li> <li> <p>One or more of the following key indicators.</p> <ol id="CD010844-list-0003"> <li> <p>Progressive and/or persistent dyspnoea.</p> </li> <li> <p>Chronic cough.</p> </li> <li> <p>Chronic sputum production.</p> </li> <li> <p>History of exposure to risk factors (tobacco smoke, smoke from home cooking and heating fuels, occupational dusts and chemicals). </p> </li> </ol> </li> </ol> </p> </section> <section id="CD010844-sec-0042"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared any of the following therapies versus any other.</p> <p> <ol id="CD010844-list-0004"> <li> <p>LABA (formoterol, salmeterol, indacaterol).</p> </li> <li> <p>LAMA (tiotropium, aclidinium bromide, glycopyrronium bromide).</p> </li> <li> <p>ICS (budesonide, fluticasone, mometasone).</p> </li> <li> <p>LABA/ICS combination (formoterol/budesonide, formoterol/mometasone, salmeterol/fluticasone).</p> </li> <li> <p>Placebo.</p> </li> </ol> </p> <p>Treatment classes and individual treatments were compared versus every other using a class‐model network meta‐analysis. The list of included treatments comprised commonly used agents within each class. </p> <p>Participants were allowed other concomitant COPD medications as prescribed by their healthcare practitioner, provided these medications were not part of the trial treatment under study. </p> </section> <section id="CD010844-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>For studies of six months' duration, we used end of study as time of analysis for all outcomes. For longer studies, we extracted data reported at six‐month and 12‐month intervals when available. Two measures of efficacy were chosen as outcomes because previous network meta‐analyses have primarily assessed safety outcomes (mortality, <a href="./references#CD010844-bbs2-0161" title="DongY , LinH , ShauW , WuY , ChangC , LaiM . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68:48‐56. ">Dong 2013</a>; exacerbations and adverse events, <a href="./references#CD010844-bbs2-0157" title="DecramerML , HananiaNA , Lotvall , JO , YawnBP . The safety of long‐acting β2‐agonistsin the treatment of stable chronic obstructive pulmonary disease. International Journal of COPD2013;8:53‐64. ">Decramer 2013</a>). </p> <section id="CD010844-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010844-list-0005"> <li> <p>Quality of life (measured as change from baseline assessed with St George's Respiratory Questionnaire (SGRQ)). </p> </li> <li> <p>Trough FEV<sub>1</sub> (change in mL from baseline). </p> </li> </ol> </p> <section id="CD010844-sec-0045"> <h6 class="title">Cost‐effectiveness</h6> <p>We did not carry out a formal cost‐effectiveness analysis, but we sought to identify economic evaluations that have compared the included interventions to supplement the main systematic review of effects. These are summarised in a short commentary in the discussion. </p> </section> </section> </section> </section> <section id="CD010844-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010844-sec-0047"> <h4 class="title">Electronic searches</h4> <p>To avoid duplication of effort, we first identified RCTs for inclusion by searching for relevant Cochrane systematic reviews. Cochrane systematic reviews use extensive search strategies that include several databases, manufacturers' websites and handsearching of conference abstracts. We searched the Cochrane Database of Systematic Reviews (CDSR) in <i>The Cochrane Library</i> (2013, Issue 7) to look for all Cochrane systematic reviews on COPD, using the search strategy provided in <a href="./appendices#CD010844-sec-0117">Appendix 1</a>, and from those, we handpicked the reviews that included relevant comparisons. From these reviews, we identified individual RCTs that met our inclusion criteria. </p> <p>In addition, we ran a search on the Cochrane Airways Group Register (CAGR) of trials (see <a href="./appendices#CD010844-sec-0118">Appendix 2</a> for details of the Register) to find studies that may have been missed in the review search (e.g. because of discrepancies in inclusion criteria between individual reviews and this network, as a result of review searches more than 12 months out of date or when no reviews existed for a particular comparison). The search was done according to guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010844-bbs2-0167" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org2011. ">Higgins 2011</a>) and in consultation with an information specialist (see <a href="./appendices#CD010844-sec-0124">Appendix 3</a> for the search strategy). No date or language restrictions were applied. We searched NHS Economic Evaluation Database (EED) and Health Economic Evaluations Database (HEED) for economic evaluations using the strategy provided in <a href="./appendices#CD010844-sec-0117">Appendix 1</a>, adapted as appropriate. </p> </section> </section> <section id="CD010844-sec-0048"> <h3 class="title" id="CD010844-sec-0048">Data collection and analysis</h3> <section id="CD010844-sec-0049"> <h4 class="title">Selection of studies</h4> <p>One review author assessed for inclusion all potentially eligible reviews retrieved through the search and assessed all potentially eligible RCTs within these reviews (KMK). The CAGR database search was sifted by the same review author, and uncertainties were resolved by discussion with a second review author (CJC). </p> </section> <section id="CD010844-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>For the following characteristics, one review author extracted information for all included RCTs from their published reports (KMK) if they were already included in a Cochrane review. </p> <p> <ol id="CD010844-list-0006"> <li> <p>Individual trial study characteristics (design, duration, location, participant inclusion/exclusion criteria, funding). </p> </li> <li> <p>Trial arms of interest (drug, dose, inhaler type, allowed co‐medications).</p> </li> <li> <p>Individual trial population details: mean baseline lung function, pack‐years, age and % male. </p> </li> <li> <p>Individual trial outcome data.</p> </li> </ol> </p> <p>Information from studies identified in other reviews was subsequently cross‐checked (data in each of the existing reviews were extracted and verified by at least two review authors). Inconsistencies and uncertainties were resolved by consultation with a second review author (CJC). </p> <section id="CD010844-sec-0051"> <h5 class="title">Assessing transitivity (similarity of participants, interventions and trial methodology)</h5> <p>The sets of trials for each treatment must be similar in their distribution of effect modifiers to permit conclusions based on a network meta‐analysis combining direct and indirect evidence (<a href="./references#CD010844-bbs2-0153" title="CiprianiA , HigginsJPT , GeddesJR , SalantiGS . Conceptual and technical challenges in network meta‐analysis. Annals of Internal Medicine2013;159(2):130‐7. ">Cipriani 2013</a>). We constructed summary tables organised by class pair‐wise comparisons (e.g. LABA vs ICS, LAMA vs placebo) to assess clinical and methodological similarities of the trials and their populations. </p> </section> </section> <section id="CD010844-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Although existing reviews were used to identify RCTs, data and methodological quality were dealt with at an individual trial level. One review author extracted information related to risk of bias for all trials and subsequently cross‐checked judgements from existing reviews, standardising ratings across them for consistency. Judgements were made for the following domains in each study in accordance with recommendations provided in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010844-bbs2-0168" title="HigginsJPT , JacksonD , BarrettJK , LuG , AdesAE , WhiteIR . Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies. Research Synthesis Methods2012; Vol. 3, issue 2:98‐110. ">Higgins 2012</a>). </p> <p> <ol id="CD010844-list-0007"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding (performance bias and detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting.</p> </li> </ol> </p> <p>We did not exclude trials on the basis of risk of bias but conducted sensitivity analyses to explore the effects of including unblinded study comparisons. </p> </section> <section id="CD010844-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010844-sec-0054"> <h5 class="title">Direct pairwise meta‐analysis</h5> <p>We analysed data for the two continuous outcomes as fixed‐effect mean differences (MDs) with 95% confidence intervals (CIs) and a fixed‐effect model. The fixed‐effect model assumes that each study is estimating exactly the same intervention effect, and the random‐effects model assumes that estimated intervention effects are not all the same but follow a normal distribution across studies. </p> <p>Data were extracted and analysed as change from baseline in all studies, and this was extracted from text or tables or was calculated from figures when necessary. Associated variance for change per arm was not always available (or could not be derived from the presented information), and in these cases we used available data from other trials to estimate a population variance. For SGRQ and trough FEV<sub>1</sub>, we calculated the mean of available standard deviations (SDs) for change scores, which was weighted by sample size. </p> </section> <section id="CD010844-sec-0055"> <h5 class="title">Network meta‐analysis</h5> <p>We conducted a network meta‐analysis (NMA) to estimate the effect for each class and for each individual intervention using Markov chain Monte Carlo methods implemented in WinBUGS 1.4.3. Analyses were based on a class model, which assumes that effects of individual treatments within a class are exchangeable and are distributed around a class mean (<a href="./references#CD010844-bbs2-0154" title="CooperNJ , SuttonAJ , MorrisD , AdesAE , WeltonNJ . Addressing between‐study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non‐rheumatic atrial fibrillation. Statistics in Medicine2009;28:1861‐81. ">Cooper 2009</a>). Correlations in multiarm trials were accounted for in the model, which was adapted from <a href="./references#CD010844-bbs2-0159" title="DiasS , SuttonAJ , AdesAE , WeltonNJ . Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta‐analysis of randomized controlled trials. Medical Decision Making2013;33:607‐17. [DOI: 10.1177/0272989X12458724] ">Dias 2013</a>. Non‐informative normal priors were used for class effects, and Uniform (0,5) and (0,100) prior distributions were used for between‐trials and between‐classes heterogeneity SDs for SGRQ and FEV<sub>1</sub>, respectively. Three chains with different initial values were run simultaneously to assess convergence using Brooks‐Gelman–Rubin diagnostic plots. The first 20,000 (fixed‐effect models) or 40,000 iterations (random‐effects models) were discarded, and 50,000 further iterations were run, on which all estimates are based. We decided whether to use a fixed‐effect or a random‐effects approach on the basis of model fit statistics and deviance information criteria (DIC) (<a href="./references#CD010844-bbs2-0159" title="DiasS , SuttonAJ , AdesAE , WeltonNJ . Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta‐analysis of randomized controlled trials. Medical Decision Making2013;33:607‐17. [DOI: 10.1177/0272989X12458724] ">Dias 2013</a>; <a href="./references#CD010844-bbs2-0191" title="SpiegelhalterDJ , BestNG , CarlinBP , van derLindeA . Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society. Series B (Statistical Methodology)2002;64(4):583‐639. ">Spiegelhalter 2002</a>), as well as the amount of heterogeneity present in the pair‐wise meta‐analyses. The model with lower values on the DIC was preferred, with differences of three or more units considered meaningful. If two models had similar DIC, the simplest model (i.e. fixed‐effect) was preferred. </p> </section> </section> <section id="CD010844-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>No unit of analysis issues were noted, as we did not analyse any dichotomous data.</p> </section> <section id="CD010844-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>When data or study characteristics were not reported in the primary publication, we searched clinical trial reports, trial registries and drug company websites to look for additional data. When possible, we used data from intention‐to‐treat (ITT) analyses from all randomly assigned participants. </p> </section> <section id="CD010844-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the presence of statistical heterogeneity (I<sup>2</sup> &gt; 30%) in the direct pair‐wise meta‐analysis, we analysed data using a random‐effects model and investigated possible sources. They could be of a clinical and methodological nature (i.e. differences between individual studies) in study design (inclusion/exclusion criteria, study duration), participants' baseline characteristics (disease severity, co‐morbidities, age, gender), risk of bias (open vs blinded studies) or study sponsorship. The extent of heterogeneity observed informed our decision of whether to use fixed‐effect or random‐effects models for the network meta‐analysis. </p> <p>For the network meta‐analysis, we assessed the extent to which direct evidence and indirect evidence were consistent both qualitatively and statistically (<a href="./references#CD010844-bbs2-0160" title="DiasS , WeltonNJ , SuttonAJ , CaldwellDM , LuG , AdesAE . Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Medical Decision Making2013;33:641‐56. ">Dias 2013a</a>; <a href="./references#CD010844-bbs2-0178" title="LuG , AdesA . Assessing evidence consistency in mixed treatment comparisons. Journal of the American Statistical Association2006;101:447‐59. ">Lu 2006</a>). Consistency refers to the agreement between direct and one or more indirect sources of evidence in a “closed loop” of trials (i.e. a path by which three or more trials are connected, starting and ending with the same node) (<a href="./references#CD010844-bbs2-0178" title="LuG , AdesA . Assessing evidence consistency in mixed treatment comparisons. Journal of the American Statistical Association2006;101:447‐59. ">Lu 2006</a>). We assessed consistency by comparing model fit from a consistency and 'independent mean effects' model and by informally comparing output from the NMA versus estimates from the pair‐wise meta‐analyses. We used this global test to determine the presence of inconsistency and to locate areas in the network at which large inconsistencies were present. The output from the network meta‐analysis was informally compared with estimates from the pair‐wise meta‐analyses to check for broad agreement. When evidence of inconsistency was found, we further investigated potential sources of inconsistency using the node‐split approach (<a href="./references#CD010844-bbs2-0158" title="DiasS , WeltonNJ , CaldwellDM , AdesAE . Checking consistency in mixed treatment comparison meta‐analysis. Statistics in Medicine2010;29(7‐8):932‐44. ">Dias 2010</a>), as this was most appropriate given the structure of the networks. In cases in which substantial inconsistency was identified, we explored factors, including participant and design characteristics, that might contribute to inconsistency, and we restricted our analysis to a subset of trials for which the evidence might be more comparable. </p> </section> <section id="CD010844-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to minimise reporting bias from non‐publication of studies or selective outcome reporting by using a broad search strategy, and by checking references of included studies and relevant systematic reviews. For each outcome, we commented on the proportion of studies contributing data to the analysis. </p> </section> <section id="CD010844-sec-0060"> <h4 class="title">Data synthesis</h4> <p>Using a class‐model network meta‐analysis, we modelled the relative effectiveness of any two classes as a function of each class relative to a reference treatment (placebo). We prespecified five unique classes of interventions (or nodes) in the network: LABA (salmeterol, formoterol and indacaterol), LAMA (tiotropium, aclidinium bromide and glycopyrronium bromide), ICS (fluticasone, budesonide and mometasone), LABA/ICS (salmeterol/fluticasone, formoterol/budesonide and formoterol/mometasone) and placebo. We estimated the probability that each class ranks at one of the five possible positions (e.g. the best, second best, third best). We obtained estimates of each overall class effect, as well as of the effects of each treatment within the class compared with every other. Estimates for within‐class variability in treatment effects, as well as for between‐class variability in treatment effects, are presented, as are ranking probabilities, in tables and figures as appropriate. </p> </section> <section id="CD010844-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses based on baseline disease severity and dose, provided that treatments could be compared indirectly with other trial comparisons through one or more common comparators (i.e. the networks remained 'connected'). However, differences in individual doses were built into the network structure, and baseline disease severity was assessed across nodes as part of the transitivity assessment. </p> <p>For the network meta‐analysis, available data were insufficient to include baseline severity as a co‐variate as a way of exploring subgroup effects. We extracted key severity criteria for each trial individually, and we summarised the data across pair‐wise comparisons to investigate potential differences. </p> </section> <section id="CD010844-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of our analyses by performing sensitivity analyses, excluding studies from the overall analysis of high risk of bias due to lack of blinding (participants and personnel and/or outcome assessors), and by considering separately studies of different duration. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010844-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010844-sec-0063"></div> <section id="CD010844-sec-0064"> <h3 class="title">Description of studies</h3> <p>Basic study characteristics, including duration, intervention details and population characteristics, are summarised in <a href="#CD010844-tbl-0001">Table 1</a>, and full details of each included study can be found in <a href="./references#CD010844-sec-0136" title="">Characteristics of included studies</a>. </p> <div class="table" id="CD010844-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">All included studies—summary characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weeks</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arms included<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% male</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% pred FEV<sub>1b</sub> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pack‐years<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0002" title="JonesP , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPE , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64(Suppl IV):A168 [P213]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. ">ACCLAIM 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0003" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLaim/COPD ii: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM II 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0004" title="AnzuetoA , FergusonG , FeldmanG , SelbertA , ChinskyK , EmmettA , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 with salmeterol on COPD exacerbations [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D40. AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A1502 [Poster #K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):1‐9. GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg BID with salmeterol DISKUS 50mcg BID on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). ">Anzueto 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>indacaterol, tiotropium, glycopyrronium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0009" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0014" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms and delays exacerbations in patients with COPD previously maintained on ICS [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [155]. ">Calverley 2003b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mometasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mometasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, formoterol/budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0018" title="AstraZeneca . A 6‐month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with chronic obstructive pulmonary disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD‐037‐0709. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012). BogdanM , ElirazA , McKinnonC , NihlenU , RadeczkyE , SolimanS , et al. Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1578. CampbellM , ElirazA , JohanssonG , TornlingG , NihlénU , BengtssonT , et al. Formoterol for maintenance and as‐needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine2005;99(12):1511‐20. CampbellM , RabeKF , AnderssonA . Formoterol turbuhaler for maintenance and as‐needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 Poster 417. ElirazA , BengtssonT , BogdanM , CoenenPDM , JohansonG , OsmanilevD , et al. Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1580. ">Campbell 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0019" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology &amp; Therapeutics2005;18(2):75‐81. CasaburiR , MahlerDA , JonesPW , WannerA , SanPG , ZuWallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5s. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD conference; November 14‐15; Arlington, Virginia. 2003:Abstract no: 1189. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (Spiriva), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics2007;8(2):123‐35. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerSJPW , SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. Zu WallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW , et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ">Casaburi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0020" title="ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal [Revue canadienne de pneumologie]2007;14(8):465‐72. ">Chan 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, mometasone, formoterol/mometasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>indacaterol (2), tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0026" title="DusserD , BravoML , IaconoP , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. DusserD , BravoML , IaconoP , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , BravoML , IanonoP , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , VielK , BravoML , IaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , IanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0028" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multicenter trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. DalalAA , StCharlesM , PetersenHV , RobertsMH , BlanchetteCM , Manavi‐ZieverinkK . Cost‐effectiveness of combination fluticasone propionate‐salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2010;5:179‐87. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respiratory Medicine2008;102(8):1099‐108. SCO40043G . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS Â® 250/50mcg bid with salmeterol DISKUS Â® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/study/SCO40043#ps (accessed 3 March 2014). [] ">Ferguson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>glycopyrronium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>glycopyrronium, tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0034" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). KardosP , WenckerM . Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1944. KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(2):144‐9. VogelmeierC , WenckerM , GlaabT , KardosP . Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QOL) more than salmeterol (SAL) alone in COPD [Abstract]. Norwegian Thoracic Society 42nd Nordic Lung Conference; June 9‐11; Trondheim. 2005; Vol. 15, issue Suppl 22. VogelmeierCF , WenckerM , GlaabTH , KardosP . Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A110 [Poster J8]. ">Kardos 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone (2), salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0037" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary diseases [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1584. ">Laptseva 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, tiotropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0040" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, Orlando. 2004:A84. NiewoehnerDE , LokhnyginaY , RiceK , KuschnerWG , SharafkhanehA , SarosiGA , et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest2007;131(1):20‐8. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJADJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0042" title="OzolD , AysanT , AytemurZ , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin‐8 levels and cell percentage in stable chronic obstructive pulmonary disease patients. European Respiratory Journal2001;18(Suppl 33):212s. OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0043" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 mcg daily with placebo in chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [GSK: FLIT97] GlaxoSmithKline . A multicentre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). [GSK: FLTB3054] PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre double‐blind, placebo‐controlled study investigating the effect of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. European Respiratory Journal1997;10 Suppl 25:427S. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre, randomised, double‐blind, placebo‐controlled trial of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. ">Paggiaro 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0045" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. Powriej , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661s [P3839]. ">Powrie 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (med)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0050" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250 mcg, with salmeterol 50 mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO100470</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol/fluticasone, fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0053" title="SenderovitzT , MaltbaekN , PedersenB , NorgaardM , NielsenC , VestboJ , et al. Prednisolone followed by inhaled budesonide vs placebo in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(Suppl 25):257S. SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide/formoterol (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium (OL), glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide (3), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (med)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, mometasone, formoterol/mometasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0062" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):96 [240]. ">To 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, indacaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0063" title="TonneiAB , BravoML , BrunM , TonnelAB . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonneiAB , PerezT , GrosboisJM , BravoML , BrunM , TonnelAB . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1934. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease2008;3(2):301‐10. ">Tonnel 2008 [TIPHON]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0064" title="SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus PRN salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1589. ">Trooster 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0065" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJ , HoogstedenHC , PrinsJB . Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A798. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , MulderPGH , BogaardJM , HoogstedenHC . Inhaled fluticasone propionate (FP) has a significant effect on FEV1 of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxyJOUR species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, tiotropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0070" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com (accessed 6 March 2014). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2006;130(4 Suppl):182s. ZhengJP , YangL , WuYM , ChenP , WenZG , HuangWJ , et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest2007;132(6):1756‐63. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50 µg/fluticasone propionate 500 µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology (Carlton, Vic.)2006;11(Suppl 5):A150 [PS‐3‐9]. ">Zheng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0071" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012;28(2):257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):5225A. ">Zhong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, formoterol/budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Numbers in parentheses indicate multiple doses of the same treatment. </p> <p><sup>b</sup>Age, % predicted FEV<sub>1</sub> and pack‐years smoked are reported as means unless otherwise stated. </p> <p>bid = twice daily.</p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> <p>nr = not reported.</p> <p>PBO = placebo inhaler.</p> <p>qd = once daily.</p> </div> </div> <section id="CD010844-sec-0065"> <h4 class="title">Results of the search</h4> <p>Results of the search are presented in <a href="#CD010844-fig-0001">Figure 1</a>, broken down by the search for Cochrane reviews on the left and the electronic database search on the right. </p> <div class="figure" id="CD010844-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram.  aAll 58 studies identified in the review search were also identified in the electronic database search.  Abbreviations: CDSR = Cochrane Database of Systematic Reviews." data-id="CD010844-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.<br/> <sup>a</sup>All 58 studies identified in the review search were also identified in the electronic database search.<br/> Abbreviations: CDSR = Cochrane Database of Systematic Reviews. </p> </div> </div> </div> <p>Fourteen relevant Cochrane reviews were identified (<a href="./references#CD010844-bbs2-0151" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [Airways code: TIO5‐COP; DOI: 10.1002/14651858.CD009157] ">Chong 2012</a>; <a href="./references#CD010844-bbs2-0165" title="GeakeJB , DabscheckEJ , Wood‐BakerR . Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta‐agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 10. [Airways code: INDC‐COP; DOI: 10.1002/14651858.CD010139] ">Geake 2012</a>; <a href="./references#CD010844-bbs2-0170" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [Airways code: TIO2‐COP; DOI: 10.1002/14651858.CD008532] ">Karner 2011</a>; <a href="./references#CD010844-bbs2-0171" title="KarnerC , CatesCJ . The effect of adding inhaled corticosteroids to tiotropium and long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 9. [Airways code: TIO4‐COP; DOI: 10.1002/14651858.CD009039] ">Karner 2011a</a>; <a href="./references#CD010844-bbs2-0172" title="KarnerC , CatesCJ . Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 4. [Airways code: TIO3‐COP; DOI: 10.1002/14651858.CD008989] ">Karner 2012</a>; <a href="./references#CD010844-bbs2-0173" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [Airways code: TIO6‐COP; DOI: 10.1002/14651858.CD009285] ">Karner 2012a</a>; <a href="./references#CD010844-bbs2-0174" title="KewKM , MavergamesC , WaltersJAE . Long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 10. [Airways code: LABA‐COP; DOI: 10.1002/14651858.CD010177] ">Kew 2013</a>; <a href="./references#CD010844-bbs2-0175" title="KewKM , SeniukovichA . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 3. [Airways code: PICS‐COP; DOI: 10.1002/14651858.CD010115.pub2] ">Kew 2014</a>; <a href="./references#CD010844-bbs2-0180" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829; CCB3‐COP] ">Nannini 2012</a>; <a href="./references#CD010844-bbs2-0181" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [Airways code: CCB‐COP; DOI: 10.1002/14651858.CD003794] ">Nannini 2013</a>; <a href="./references#CD010844-bbs2-0182" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [Airways code: CCB2‐COP; DOI: 10.1002/14651858.CD006826] ">Nannini 2013a</a>; <a href="./references#CD010844-bbs2-0190" title="SpencerS , KarnerC , CatesCJ , EvansDJ . Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 12. [Airways code: IST‐COP; DOI: 10.1002/14651858.CD007033] ">Spencer 2011</a>; <a href="./references#CD010844-bbs2-0194" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 5. [Airways code: TIO1‐COP; DOI: 10.1002/14651858.CD007891] ">Welsh 2013</a>; <a href="./references#CD010844-bbs2-0197" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [Airways code: STER‐COP; DOI: 10.1002/14651858.CD002991] ">Yang 2012a</a>), including a total of 124 studies. Sixty‐six studies were excluded because of differences in the reviews' inclusion criteria, most commonly, 'duration less than six months' (n = 49), and 'cross‐over design' (n = 16). The remaining 58 studies were included in the review. </p> <p>Searching the CAGR of trials returned 2034 references, and 58 additional references were identified by searching reference lists and drug company websites. We excluded 1449 references after sifting titles and abstracts, and we reviewed full texts after studification for the remaining 643. Four hundred eighty‐six references met all inclusion criteria, most of which related to the 58 studies identified from the review search. The remaining references were collated into 13 additional studies that met the inclusion criteria. The most common reasons for excluding citations after viewing full texts were 'invalid comparison for this review' (n = 78), 'duration less than six months' (n = 46) and 'cross‐over design' (n = 29). </p> </section> <section id="CD010844-sec-0066"> <h4 class="title">Included studies</h4> <p>Seventy‐one studies met the inclusion criteria, randomly assigning 73,062 people with a diagnosis of COPD to 184 treatment arms of interest (including placebo). The number of participants included in the trials ranged from 18 (<a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>) to 7384 (<a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a>); the mean number per arm of a trial was 397. <a href="#CD010844-tbl-0001">Table 1</a> lists all 71 studies that met the inclusion criteria, along with their total duration, treatment arms relevant to the network and summary characteristics for each study population. <a href="#CD010844-tbl-0002">Table 2</a> and <a href="#CD010844-tbl-0003">Table 3</a> present pooled characteristics for each class and for individual nodes within them for studies contributing data to the SGRQ and trough FEV<sub>1</sub> data sets, respectively. </p> <div class="table" id="CD010844-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">SGRQ network composition and transitivity assessmenta </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % FEV<sub>1c</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Packs<sup>d</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13,808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.9</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Summary population data are for all study comparisons excluding those made in the 29 studies that could not be included in either the six‐month or the 12‐month SGRQ network. </p> <p><sup>b</sup>Age = mean years. </p> <p><sup>c</sup>% FEV<sub>1</sub> = mean percentage predicted FEV<sub>1</sub>. </p> <p><sup>d</sup>Packs = mean pack‐years. </p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> <p>SGRQ = St George's Respiratory Questionnaire.</p> </div> </div> <div class="table" id="CD010844-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">FEV1 network composition and transitivity assessmenta </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> %FEV<sub>1c</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Packs<sup>d</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.5</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Summary population data are for all study comparisons excluding those made in the 23 studies that could not be included in either the six‐month or the 12‐month FEV<sub>1</sub> network; all doses are given in micrograms. </p> <p><sup>b</sup>Age = mean years. </p> <p><sup>c</sup>% FEV<sub>1</sub> = mean percentage predicted FEV<sub>1</sub>. </p> <p><sup>d</sup>Packs = mean pack‐years. </p> <p>FEV1 = forced expiratory volume in one second.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> </div> </div> <section id="CD010844-sec-0067"> <h5 class="title">Design and duration</h5> <p>All of the studies were parallel‐group, randomised controlled trials, and most were conducted at multiple centres in several countries. A vast majority were double‐blind; five included one open‐label treatment (see sensitivity analyses), a subset were double‐blind and double‐dummy and blinding was unclear in four others. </p> <p>All studies had a randomly assigned treatment period of at least 24 weeks. Similar numbers of six‐month and 12‐month studies were identified (n = 30 and n = 29, respectively), but six‐month data were available in a number of the longer trials. Twelve studies lasted between two and four years (<a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; <a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a>; <a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a>; <a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a>; <a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a>; <a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a>; <a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a>; <a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a>; <a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a>; <a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a>). For these studies, we used data measured and reported for six and 12 months in the NMA, rather than endpoint. Data entered in the six‐month analysis were reported between 24 and 32 weeks, and data included in the 12‐month networks were measured between 44 and 56 weeks in the individual studies. </p> </section> <section id="CD010844-sec-0068"> <h5 class="title">Participant inclusion and exclusion criteria</h5> <p>The trials were relatively consistent in their key inclusion and exclusion criteria. All studies required a clinical diagnosis of COPD, and most specified that this was in accordance with recent guidelines (usually <a href="./references#CD010844-bbs2-0146" title="CelliBR , MacNeeW . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal2004;23(6):932‐46. ">ATS/ERS 2004</a> or <a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). The cutoff for forced expiratory volume in one second (FEV<sub>1</sub>) expressed as the percentage predicted normal value ranged from 50% to 80%. Additional inclusion criteria that were common across trials were these: smokers or ex‐smokers with a smoking history of at least 10 pack‐years, 40 years of age or older and FEV<sub>1</sub>/FVC ratio less than 70%. </p> <p>Exclusion criteria that were common across most trials were these: history of asthma or other respiratory disease, any significant disease other than COPD and the need for supplemental oxygen. Patients who had a COPD exacerbation or upper respiratory tract infection in the run up to screening (usually within four to six weeks) were usually excluded. Trials often listed additional exclusion criteria specific to the drugs under study, such as sensitivities to active ingredients, or medical conditions that might be affected by known adverse effects. </p> </section> <section id="CD010844-sec-0069"> <h5 class="title">Baseline characteristics of participants in the trials</h5> <p>Baseline characteristics are presented for all included studies in <a href="#CD010844-tbl-0001">Table 1</a>, and for the subsets of studies contributing data to the SGRQ and FEV<sub>1</sub> analyses in <a href="#CD010844-tbl-0002">Table 2</a> and <a href="#CD010844-tbl-0003">Table 3</a>, respectively. </p> <p>In the SGRQ data set, the overall mean age per class was very similar, ranging from 62.9 to 64.5 years. In the FEV<sub>1</sub> data set, the overall mean age for each comparison was also very similar, ranging from 63.3 to 64.3. Both data sets consistently included more men than women, and the means of trial percentages were similar between and within comparisons (SGRQ range 69.5% to 82.5%, FEV<sub>1</sub> range 67.1% to 73.2%). As might be expected from variation in inclusion criteria, greater variability was noted in the summary statistics for percentage predicted FEV<sub>1</sub>, with the LABA versus LAMA comparison having somewhat higher scores in both data sets than the other classes (both means around 55% compared with 39% to 47% in the other comparisons). Overall, most population means for percentage predicted FEV<sub>1</sub> were less than 50% predicted. Mean pack‐years were between 40 and 50 for all comparisons in both data sets. In general, the data indicated a fairly consistent moderate to severe population across both outcome data sets and across direct between‐class comparisons, which satisfied the transitivity assumption. </p> </section> <section id="CD010844-sec-0070"> <h5 class="title">Characteristics of the interventions</h5> <p><a href="#CD010844-tbl-0004">Table 4</a> shows the distribution of treatment arms across all 71 included studies, organised by the five prespecified treatment classes. The text below summarises information about all 71 included studies. <a href="#CD010844-tbl-0002">Table 2</a> and <a href="#CD010844-tbl-0003">Table 3</a> show the number of studies making each class comparison represented in the SGRQ or FEV<sub>1</sub> analyses, respectively. </p> <div class="table" id="CD010844-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Distribution of studies by individual treatment node</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment node mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>LABA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol 12 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; <a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a>; </p> <p><a href="./references#CD010844-bbs2-0018" title="AstraZeneca . A 6‐month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with chronic obstructive pulmonary disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD‐037‐0709. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012). BogdanM , ElirazA , McKinnonC , NihlenU , RadeczkyE , SolimanS , et al. Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1578. CampbellM , ElirazA , JohanssonG , TornlingG , NihlénU , BengtssonT , et al. Formoterol for maintenance and as‐needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine2005;99(12):1511‐20. CampbellM , RabeKF , AnderssonA . Formoterol turbuhaler for maintenance and as‐needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 Poster 417. ElirazA , BengtssonT , BogdanM , CoenenPDM , JohansonG , OsmanilevD , et al. Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1580. ">Campbell 2005</a>; <a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; <a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a>; </p> <p><a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; </p> <p><a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a><sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol 24 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indacaterol 300 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indacaterol 600 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indacaterol 150 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol 50 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0004" title="AnzuetoA , FergusonG , FeldmanG , SelbertA , ChinskyK , EmmettA , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 with salmeterol on COPD exacerbations [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D40. AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A1502 [Poster #K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):1‐9. GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg BID with salmeterol DISKUS 50mcg BID on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). ">Anzueto 2009</a>; <a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a>; <a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; </p> <p><a href="./references#CD010844-bbs2-0028" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multicenter trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. DalalAA , StCharlesM , PetersenHV , RobertsMH , BlanchetteCM , Manavi‐ZieverinkK . Cost‐effectiveness of combination fluticasone propionate‐salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2010;5:179‐87. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respiratory Medicine2008;102(8):1099‐108. SCO40043G . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS Â® 250/50mcg bid with salmeterol DISKUS Â® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/study/SCO40043#ps (accessed 3 March 2014). [] ">Ferguson 2008</a>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0034" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). KardosP , WenckerM . Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1944. KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(2):144‐9. VogelmeierC , WenckerM , GlaabT , KardosP . Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QOL) more than salmeterol (SAL) alone in COPD [Abstract]. Norwegian Thoracic Society 42nd Nordic Lung Conference; June 9‐11; Trondheim. 2005; Vol. 15, issue Suppl 22. VogelmeierCF , WenckerM , GlaabTH , KardosP . Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A110 [Poster J8]. ">Kardos 2007</a>; <a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0050" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250 mcg, with salmeterol 50 mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO100470</a>; <a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a>; </p> <p><a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a><sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>LAMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 5 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a>; <a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a>; <a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 10 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a>; <a href="./references#CD010844-bbs2-0019" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology &amp; Therapeutics2005;18(2):75‐81. CasaburiR , MahlerDA , JonesPW , WannerA , SanPG , ZuWallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5s. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD conference; November 14‐15; Arlington, Virginia. 2003:Abstract no: 1189. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (Spiriva), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics2007;8(2):123‐35. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerSJPW , SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. Zu WallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW , et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ">Casaburi 2002</a>; <a href="./references#CD010844-bbs2-0020" title="ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal [Revue canadienne de pneumologie]2007;14(8):465‐72. ">Chan 2007</a>;<br/> <a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0026" title="DusserD , BravoML , IaconoP , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. DusserD , BravoML , IaconoP , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , BravoML , IanonoP , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , VielK , BravoML , IaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , IanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a><sup>a</sup>;<br/> <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0040" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, Orlando. 2004:A84. NiewoehnerDE , LokhnyginaY , RiceK , KuschnerWG , SharafkhanehA , SarosiGA , et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest2007;131(1):20‐8. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJADJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0045" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. Powriej , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661s [P3839]. ">Powrie 2007</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>;<br/> <a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a>; <a href="./references#CD010844-bbs2-0063" title="TonneiAB , BravoML , BrunM , TonnelAB . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonneiAB , PerezT , GrosboisJM , BravoML , BrunM , TonnelAB . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1934. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease2008;3(2):301‐10. ">Tonnel 2008 [TIPHON]</a>; <a href="./references#CD010844-bbs2-0064" title="SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus PRN salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1589. ">Trooster 2011</a><sup>a</sup>;<br/> <a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aclidinium bromide 200 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0002" title="JonesP , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPE , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64(Suppl IV):A168 [P213]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. ">ACCLAIM 2009</a>; <a href="./references#CD010844-bbs2-0003" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLaim/COPD ii: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM II 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aclidinium bromide 200 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a>; <a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aclidinium bromide 400 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a>; <a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycopyrronium bromide 50 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a>; <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 320‐400 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0037" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary diseases [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1584. ">Laptseva 2002</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0042" title="OzolD , AysanT , AytemurZ , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin‐8 levels and cell percentage in stable chronic obstructive pulmonary disease patients. European Respiratory Journal2001;18(Suppl 33):212s. OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0053" title="SenderovitzT , MaltbaekN , PedersenB , NorgaardM , NielsenC , VestboJ , et al. Prednisolone followed by inhaled budesonide vs placebo in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(Suppl 25):257S. SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; </p> <p><a href="./references#CD010844-bbs2-0071" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012;28(2):257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):5225A. ">Zhong 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 750‐1000 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0009" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a>; <a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone 250 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone 500 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a>; <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>;<br/> <a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a>; <a href="./references#CD010844-bbs2-0043" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 mcg daily with placebo in chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [GSK: FLIT97] GlaxoSmithKline . A multicentre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). [GSK: FLTB3054] PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre double‐blind, placebo‐controlled study investigating the effect of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. European Respiratory Journal1997;10 Suppl 25:427S. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre, randomised, double‐blind, placebo‐controlled trial of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. ">Paggiaro 1998</a>; <a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a>;<br/> <a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0065" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJ , HoogstedenHC , PrinsJB . Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A798. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , MulderPGH , BogaardJM , HoogstedenHC . Inhaled fluticasone propionate (FP) has a significant effect on FEV1 of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxyJOUR species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a><sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone 400 bid or 800 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0014" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms and delays exacerbations in patients with COPD previously maintained on ICS [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [155]. ">Calverley 2003b</a>; <a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a>; <a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>LABA/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/bud 12/160 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; <a href="./references#CD010844-bbs2-0071" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012;28(2):257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):5225A. ">Zhong 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/bud 12/320 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; </p> <p><a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/mom 12/200 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/mom 12/400 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol/flut 50/250 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0004" title="AnzuetoA , FergusonG , FeldmanG , SelbertA , ChinskyK , EmmettA , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 with salmeterol on COPD exacerbations [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D40. AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A1502 [Poster #K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):1‐9. GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg BID with salmeterol DISKUS 50mcg BID on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). ">Anzueto 2009</a>; <a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a>; <a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol/flut 50/500 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; </p> <p><a href="./references#CD010844-bbs2-0028" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multicenter trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. DalalAA , StCharlesM , PetersenHV , RobertsMH , BlanchetteCM , Manavi‐ZieverinkK . Cost‐effectiveness of combination fluticasone propionate‐salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2010;5:179‐87. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respiratory Medicine2008;102(8):1099‐108. SCO40043G . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS Â® 250/50mcg bid with salmeterol DISKUS Â® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/study/SCO40043#ps (accessed 3 March 2014). [] ">Ferguson 2008</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a>; <a href="./references#CD010844-bbs2-0050" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250 mcg, with salmeterol 50 mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO100470</a>; <a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a>; <a href="./references#CD010844-bbs2-0070" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com (accessed 6 March 2014). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2006;130(4 Suppl):182s. ZhengJP , YangL , WuYM , ChenP , WenZG , HuangWJ , et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest2007;132(6):1756‐63. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50 µg/fluticasone propionate 500 µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology (Carlton, Vic.)2006;11(Suppl 5):A150 [PS‐3‐9]. ">Zheng 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PBO</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a>; <a href="./references#CD010844-bbs2-0002" title="JonesP , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPE , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64(Suppl IV):A168 [P213]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. ">ACCLAIM 2009</a>; <a href="./references#CD010844-bbs2-0003" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLaim/COPD ii: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM II 2009</a>; <a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a>; </p> <p><a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a>; <a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a>; <a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0009" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a>; </p> <p><a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a>; <a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a>; <a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; </p> <p><a href="./references#CD010844-bbs2-0014" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms and delays exacerbations in patients with COPD previously maintained on ICS [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [155]. ">Calverley 2003b</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; <a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a>; <a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a>; </p> <p><a href="./references#CD010844-bbs2-0018" title="AstraZeneca . A 6‐month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with chronic obstructive pulmonary disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD‐037‐0709. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012). BogdanM , ElirazA , McKinnonC , NihlenU , RadeczkyE , SolimanS , et al. Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1578. CampbellM , ElirazA , JohanssonG , TornlingG , NihlénU , BengtssonT , et al. Formoterol for maintenance and as‐needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine2005;99(12):1511‐20. CampbellM , RabeKF , AnderssonA . Formoterol turbuhaler for maintenance and as‐needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 Poster 417. ElirazA , BengtssonT , BogdanM , CoenenPDM , JohansonG , OsmanilevD , et al. Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1580. ">Campbell 2005</a>; <a href="./references#CD010844-bbs2-0019" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology &amp; Therapeutics2005;18(2):75‐81. CasaburiR , MahlerDA , JonesPW , WannerA , SanPG , ZuWallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5s. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD conference; November 14‐15; Arlington, Virginia. 2003:Abstract no: 1189. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (Spiriva), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics2007;8(2):123‐35. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerSJPW , SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. Zu WallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW , et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ">Casaburi 2002</a>; <a href="./references#CD010844-bbs2-0020" title="ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal [Revue canadienne de pneumologie]2007;14(8):465‐72. ">Chan 2007</a>; <a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; </p> <p><a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0026" title="DusserD , BravoML , IaconoP , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. DusserD , BravoML , IaconoP , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , BravoML , IanonoP , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , VielK , BravoML , IaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , IanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>; </p> <p><a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a>; <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a>; <a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0037" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary diseases [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1584. ">Laptseva 2002</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a>; <a href="./references#CD010844-bbs2-0040" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, Orlando. 2004:A84. NiewoehnerDE , LokhnyginaY , RiceK , KuschnerWG , SharafkhanehA , SarosiGA , et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest2007;131(1):20‐8. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJADJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0042" title="OzolD , AysanT , AytemurZ , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin‐8 levels and cell percentage in stable chronic obstructive pulmonary disease patients. European Respiratory Journal2001;18(Suppl 33):212s. OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a>; <a href="./references#CD010844-bbs2-0043" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 mcg daily with placebo in chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [GSK: FLIT97] GlaxoSmithKline . A multicentre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). [GSK: FLTB3054] PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre double‐blind, placebo‐controlled study investigating the effect of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. European Respiratory Journal1997;10 Suppl 25:427S. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre, randomised, double‐blind, placebo‐controlled trial of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. ">Paggiaro 1998</a>; </p> <p><a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0045" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. Powriej , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661s [P3839]. ">Powrie 2007</a>; <a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a>; <a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a>; </p> <p><a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a>; <a href="./references#CD010844-bbs2-0053" title="SenderovitzT , MaltbaekN , PedersenB , NorgaardM , NielsenC , VestboJ , et al. Prednisolone followed by inhaled budesonide vs placebo in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(Suppl 25):257S. SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a>; <a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a>; </p> <p><a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>; <a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; <a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a>; </p> <p><a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; <a href="./references#CD010844-bbs2-0062" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):96 [240]. ">To 2011</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0063" title="TonneiAB , BravoML , BrunM , TonnelAB . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonneiAB , PerezT , GrosboisJM , BravoML , BrunM , TonnelAB . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1934. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease2008;3(2):301‐10. ">Tonnel 2008 [TIPHON]</a>; <a href="./references#CD010844-bbs2-0064" title="SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus PRN salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1589. ">Trooster 2011</a>; <a href="./references#CD010844-bbs2-0065" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJ , HoogstedenHC , PrinsJB . Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A798. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , MulderPGH , BogaardJM , HoogstedenHC . Inhaled fluticasone propionate (FP) has a significant effect on FEV1 of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxyJOUR species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a>; <a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0070" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com (accessed 6 March 2014). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2006;130(4 Suppl):182s. ZhengJP , YangL , WuYM , ChenP , WenZG , HuangWJ , et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest2007;132(6):1756‐63. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50 µg/fluticasone propionate 500 µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology (Carlton, Vic.)2006;11(Suppl 5):A150 [PS‐3‐9]. ">Zheng 2006</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Studies not contributing data to either outcome. </p> <p>bid = twice daily.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> <p>PBO = placebo inhaler.</p> <p>qd = once daily.</p> </div> </div> <p>Lists of allowed co‐medications varied between studies, but participants were always allowed a short‐acting beta‐agonist reliever inhaler and short‐term treatment for exacerbations during the randomised period (course of oral corticosteroids or antibiotics). </p> <section id="CD010844-sec-0071"> <h6 class="title">1. Long‐acting beta<sub>2</sub>‐agonists (LABAs) </h6> <p>Thirty‐seven LABA treatment arms were identified across 30 studies (n = 15,266). Twelve studies included a formoterol arm with treatment given at 12 mcg twice daily, and <a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a> also randomly assigned participants to a higher dose of twice‐daily 24 mcg. Formoterol was most commonly given via a dry powder inhaler but sometimes via a metered‐dose inhaler (to retain blinding in the newer multiarm mometasone studies). Salmeterol was given at 50 mcg twice daily in 17 studies (n = 9019), primarily via the Diskus device. Indacaterol, a once‐daily preparation, was given as 150 mcg in three studies (<a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a>) and as 300 mcg in three studies (<a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0062" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):96 [240]. ">To 2011</a>), one of which also used a higher dose of 600 mcg. <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> was conducted in two stages, and the data derived are for the four randomly assigned groups from stage 2. </p> </section> <section id="CD010844-sec-0072"> <h6 class="title">2. Long‐acting muscarinic antagonists (LAMAs)</h6> <p>Thirty‐four LAMA treatment arms were included across 28 studies (n = 21,805). Most studies used tiotropium 18 mcg daily, delivered most often via the HandiHaler. Six studies included two arms that met criteria for inclusion in the LAMA category: <a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> used two tiotropium doses (5 and 10 mcg daily via Respimat), <a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a> and <a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> used two aclidinium doses (200 and 400 mcg daily) and <a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>, <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a> and <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> included both glycopyrronium 50 mcg and open‐label tiotropium. Two additional glycopyrronium studies used 50 mcg via the Breezhaler, and two other aclidinium studies used the lower of the two doses via the Genuair device. Two other tiotropium studies used the Respimat device to deliver 5 mcg daily (<a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a> and <a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a>). </p> </section> <section id="CD010844-sec-0073"> <h6 class="title">3. Inhaled corticosteroids (ICSs)</h6> <p>Twenty‐seven studies included an ICS arm (n = 6788), with two including two doses of the same drug that were relevant to the review (<a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a>; <a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>). Twelve studies (n = 3491) reported a fluticasone arm: two studies used 250 mcg twice daily, and the rest 500 mcg, delivered most often via the Diskus device. Twelve studies with around half as many people used budesonide (n = 1900): two at the higher dose of 800 mcg twice daily, and the rest at 400 mcg, with both doses delivered via dry powder inhalers. Mometasone was used in four studies (n = 1397) and was given as 400 mcg twice daily or 800 mcg once daily. </p> </section> <section id="CD010844-sec-0074"> <h6 class="title">4. Long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combinations (LABA/ICS) </h6> <p>Thirty LABA/ICS treatment arms were identified in 25 studies (n = 9727). Three studies used two budesonide doses (160 mcg and 320 mcg; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>), and seven additional studies used only the higher dose (total N = 3221). Two identically designed studies included two formoterol/mometasone doses each, 200 and 400 mcg (n = 888). Sixteen studies had a salmeterol/fluticasone arm (n = 5618), six at the lower ICS dose of 50/250 mcg and 11 at the higher dose of 50/500 mcg. All LABA/ICS inhalers were prescribed for twice‐daily use and drugs were delivered by dry powder or pressurised metered‐dose inhalers. </p> </section> <section id="CD010844-sec-0075"> <h6 class="title">5. Placebo</h6> <p>Most studies included a placebo control arm (n = 55), which consisted of a total of 19,476 people. Inhalers varied across studies depending on the device used to deliver the study drugs. Once‐daily and twice‐daily placebos were combined in the same node as the reference treatment to increase the number of comparisons that could be made. </p> </section> </section> <section id="CD010844-sec-0076"> <h5 class="title">Transitivity (similarity of participants, interventions and trial methodology)</h5> <p> <ol id="CD010844-list-0008"> <li> <p><b>Inclusion and exclusion criteria</b>, as described above, did not vary systematically across classes; although variation in the allowed co‐medications and in the maximum allowed percentage predicted FEV<sub>1</sub> was noted, these did not translate to systematic differences in the characteristics of the recruited population. </p> </li> <li> <p><b>Baseline characteristics</b> were varied between individual trials, but summary baseline characteristics were comparable across pair‐wise comparisons between classes for both outcome data sets (see above and <a href="#CD010844-tbl-0002">Table 2</a>; <a href="#CD010844-tbl-0003">Table 3</a>). Mean percentage predicted FEV<sub>1</sub> was somewhat higher in the LABA versus LAMA comparisons conducted in two studies (55% vs 39% to 47% in the other comparisons). </p> </li> <li> <p><b>Intervention characteristics</b> introduced some potential sources of systematic variation between trials, notably as a result of the devices used and the dosing schedule. However, as all nodes showed variation in the delivery device used and in once‐daily and twice‐daily regimens, we did not consider these factors to violate assumptions needed for indirect comparisons. The placebo‐controlled trials used matching inhalers to control for bias at a trial level, and variation within classes was similar, so we considered a combined placebo class valid as the reference treatment (regardless of device or dosing regimen). </p> </li> <li> <p><b>Methodology</b> was similar across trials, and no issues with the comparability of trial duration arose, as we included only data relevant to the time points specified. Funding sources varied across classes, depending on the drug manufacturers, but this variability did not translate into systematic differences in the way that trials were conducted, nor in the populations recruited (i.e. similar inclusion criteria, baseline characteristics and study designs). Average sample size per class was higher in the LAMA trials (659 and 633 for SGRQ and FEV<sub>1</sub>, respectively) than in the four other classes (range 189 to 471 across both outcome data sets), but variation within the classes was comparable. </p> </li> </ol> </p> </section> <section id="CD010844-sec-0077"> <h5 class="title">Outcomes and analysis structure</h5> <p>For both outcomes, the overall fit of the network meta‐analysis class model was compared with the fit of a class model without the consistency assumption (broadly equivalent to a pair‐wise meta‐analysis with random class effects), using the total residual deviance. Statistical inconsistency was not significant on SGRQ at 12 months nor on the FEV<sub>1</sub> analyses (six and 12 months). However some evidence of inconsistency was noted in the network for SGRQ at six months. This was investigated further using the node‐split approach (<a href="./references#CD010844-bbs2-0158" title="DiasS , WeltonNJ , CaldwellDM , AdesAE . Checking consistency in mixed treatment comparison meta‐analysis. Statistics in Medicine2010;29(7‐8):932‐44. ">Dias 2010</a>), which found some evidence of inconsistency (P value 0.01, although multiple comparisons were made) in the direct evidence comparing indacaterol 150 mcg and tiotropium 18 mcg. We investigated the possible clinical explanation for this inconsistency and found that studies directly comparing these two treatments delivered tiotropium open‐label, which affected comparability with other tiotropium studies, and increased risk of bias (see sensitivity analyses). The dose was misclassified in one study comparing salmeterol versus salmeterol/fluticasone combination (salmeterol/fluticasone as 50/500 bid instead of 50/250). Because the study did not appear in the main six‐month results nor change the class comparisons, we did not rerun the analyses. </p> <section id="CD010844-sec-0078"> <h6 class="title">St George's Respiratory Questionnaire (SGRQ)</h6> <p>The SGRQ is a well‐validated and widely used measure of health status in patients with chronic airflow limitation; the total score ranges from zero (perfect health) to 100 (most severe status) and includes the three components of symptoms, activity and impacts. </p> <p>In the main network of effects at six months, 18 of 25 possible treatments were represented across 72 treatment arms in 25 studies (n = 27,024). The fixed‐effect model was preferred, as statistical heterogeneity was not significant. We extracted and analysed data as change from baseline per arm and estimated population variance on the basis of data from studies reporting variance for change per arm (see <a href="#CD010844-sec-0053">Measures of treatment effect</a>). The mean of SDs, weighted by sample size, was imputed as 14 when variance for change could not be obtained. </p> <p>The 12‐month analysis contained slightly fewer data and had a broadly similar structure (containing data for 19 treatment comparisons in 24 studies). The fixed‐effect model was preferred, as with the six‐month analysis, but <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a> showed some lack of fit. Data from four studies were removed from the six‐month network in the blinding sensitivity analysis (<a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>), and data from two studies were removed from the 12‐month network (<a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>). </p> <p>The network structure for SGRQ at six months is shown in <a href="#CD010844-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD010844-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Network structures for both outcomes at six months." data-id="CD010844-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network structures for both outcomes at six months.</p> </div> </div> </div> </section> <section id="CD010844-sec-0079"> <h6 class="title">Trough forced expiratory volume in one second (FEV<sub>1</sub>) </h6> <p>In the main network of effects at six months, 20 of 25 possible treatments were represented across 82 treatment arms in 31 studies (n = 29,271). A random‐effects model was preferred, as the fixed‐effect model has very poor fit. Data for eight studies were available only as treatment contrasts, and the rest were entered as change from baseline per arm, along with the associated variance. For trials reporting treatment contrasts, we included co‐variance, which was calculated as the variance of the mean in the control arm (placebo for all trials). For the rest of the trials, missing variance for change from baseline was imputed as 283 (mL) from the mean of available SDs weighted by sample size. </p> <p>One very small trial was excluded from the six‐month analysis (<a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a>, n = 34) because of the unusually high dropout from already very small groups (seven of 17 dropped out in both groups). The study showed very poor fit, even in random‐effects models, because the results contradicted all other trials. </p> <p>The 12‐month analysis contained fewer data (19 treatments compared in 21 studies) but again had a structure broadly similar to the main six‐month analysis. As with the six‐month analysis, the random‐effects model was preferred, as the fixed‐effect model had very poor fit. Data from the same four studies were removed from the six‐month and 12‐month networks, as for the SGRQ sensitivity analyses (see <a href="#CD010844-tbl-0005">Table 5</a>). </p> <div class="table" id="CD010844-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis—blinding</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Arm removed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Analyses affected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m, SGRQ12m, FEV12m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole study (2 arms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m, SGRQ12m, FEV12m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not appear in analyses</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEV = forced expiratory volume in one second</p> <p>SGRQ = St George's Respiratory Questionnaire</p> <p>6m = six month analysis</p> <p>12m = 12 month analysis</p> </div> </div> <p>The network structure for trough FEV<sub>1</sub> at six months is shown in <a href="#CD010844-fig-0002">Figure 2</a>. </p> </section> </section> <section id="CD010844-sec-0080"> <h5 class="title">Sensitivity analyses</h5> <p>Five studies included a randomly assigned group that received tiotropium as an open‐label treatment (<a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>; <a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). As this introduced the potential for performance and assessment bias, we removed these arms from the affected networks in a risk of bias sensitivity analysis, as detailed in <a href="#CD010844-tbl-0005">Table 5</a>. Blinding led to unclear or high risk of bias in four additional studies, mainly as the result of insufficient reporting, but none of the studies reported data that could be included in the networks (<a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a>; <a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a>; <a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a>; <a href="./references#CD010844-bbs2-0062" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):96 [240]. ">To 2011</a>). </p> <p>As stated in the protocol, we analysed separately data collected at six months and at 12 months. </p> </section> </section> <section id="CD010844-sec-0081"> <h4 class="title">Excluded studies</h4> <p>Sixty‐six studies were excluded from the 14 relevant Cochrane reviews, and five others that came up in the electronic database search are recorded in <a href="./references#CD010844-sec-0137" title="">Characteristics of excluded studies</a>. We did not record every reference excluded after the full‐text sift (n = 157), as review of the full paper revealed that most trials were apparently of less than six months' duration, or they compared treatments that were not within the scope of the study. </p> </section> </section> <section id="CD010844-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>Methodological quality of the included studies was generally good. Across all six domains, around 60% of judgements were 'low risk', and 13% were 'high' risk. It is unlikely that the evidence presented in this review is affected by biases associated with unacceptable sequence generation, and most trials were double‐blinded. The most common reasons for probable bias were attrition and selective reporting in the individual trials. A degree of uncertainly regarding the risk of bias associated with allocation concealment and blinding of outcome assessors was due mostly to insufficient reporting. Risk of bias judgements for all of the included studies are summarised in <a href="#CD010844-fig-0003">Figure 3</a> </p> <div class="figure" id="CD010844-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010844-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010844-sec-0083"> <h4 class="title">Allocation</h4> <section id="CD010844-sec-0084"> <h5 class="title">Random sequence generation</h5> <p>All studies were randomised trials, and none were given high risk ratings for either of the selection bias domains. Most were funded by drug manufacturers with whom the authors had had previous contact to confirm methods of sequence generation. As such, all studies were considered to be at low risk of bias for this domain, with the exception of six studies for which only a conference abstract was available (rated unclear). Of these, none appeared in the SGRQ data set, and only two contributed FEV<sub>1</sub> data. </p> </section> <section id="CD010844-sec-0085"> <h5 class="title">Allocation concealment</h5> <p>A third of studies described methods of allocation concealment (interactive voice response system or sealed envelopes) and were rated as having low risk of bias (n = 24). The remaining studies did not explicitly describe their methods and were rated as unclear. This information is likely to be conservative given the high proportion of industry‐funded trials, which generally have rigorous controls for selection bias. </p> </section> </section> <section id="CD010844-sec-0086"> <h4 class="title">Blinding</h4> <section id="CD010844-sec-0087"> <h5 class="title">Blinding of participants and personnel</h5> <p>A large majority of trials stated that they were double‐blind, which, unless otherwise stated, was understood to pertain to at least participants and personnel. For this reason, more than 85% of the trials were rated at low risk for performance bias. Seven trials (10%) were given a high risk of bias rating, which was due mostly to the fact that one arm of the trial was delivered open‐label. In these instances, treatment comparisons that did not involve the open‐label arm were not affected, and sensitivity analyses removing these arms assessed the effects of removing these high‐risk comparisons from the networks. </p> </section> <section id="CD010844-sec-0088"> <h5 class="title">Blinding of outcome assessors</h5> <p>A third of trials gave enough detail to warrant a low risk of bias rating, which was usually obtained from the clinicaltrials.gov registration. Most trials did not describe how outcomes were assessed in sufficient detail to rule out bias associated with unblinded outcome assessors and hence were rated as unclear. As with allocation concealment, an unclear rating for studies not explicitly describing outcome assessor blinding is likely to be conservative. Five studies were rated as high risk for the same reasons outlined for the participant and personnel domain. </p> </section> </section> <section id="CD010844-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>Around half the trials were judged to be at low risk of bias because the level of dropout was acceptable and balanced between groups, or because sufficient efforts were made to impute missing data. Twenty‐two trials were given a high risk rating, indicating a significant risk that unbalanced or especially high attrition may have compromised the validity of the results, and 13 were rated as unclear. However, several of the high risk ratings were given to the longer trials (two years or longer), in which a significant proportion of participants had dropped out by the end of the trial. By including data at the six‐month and 12‐month time points rather than at endpoint in these unusual trials, the risk from attrition may be reduced, as higher percentages of the randomly assigned populations were generally included in the earlier analyses. </p> </section> <section id="CD010844-sec-0090"> <h4 class="title">Selective reporting</h4> <p>Most trials could be linked to a prospectively registered protocol for cross‐checking of reported outcomes (on clinicaltrials.gov or manufacturers' websites). Most reported the named outcomes well in published reports, and a subset had additionally posted results summaries on clinicaltrials.gov, warranting a low risk rating (n = 43). A third were judged to be at high risk of bias, usually because outcomes stated in the protocol or important study methods were missing from published reports, regardless of whether this directly affected our analyses. Some trials were rated at high risk of bias because SGRQ or FEV<sub>1</sub> data were reported but not in an acceptable format to be combined in meta‐analysis. Although some early trials did not use the SGRQ or used a different FEV<sub>1</sub> measurement for legitimate reasons, this fact and selective outcome reporting resulted in omission of a significant proportion of relevant trials from the SGRQ and FEV<sub>1</sub> analyses. Eight were rated as unclear, usually because a protocol could not be located to confirm that all planned outcomes had been reported. </p> </section> </section> <section id="CD010844-sec-0091"> <h3 class="title" id="CD010844-sec-0091">Effects of interventions</h3> <p>For each outcome, we presented six‐month data for the main analyses, along with the number of treatments included, the number of pair‐wise comparisons made and estimates of model fit and heterogeneity. Results are presented first as class effects and second for individual treatments. As the class analysis assumes that treatments within the same class are exchangeable and are distributed around a class mean, we have also outlined the effects of fitting the class model on individual treatment effects. </p> <p>Results from the 12‐month networks for each outcome are also presented (shown graphically alongside the six‐month class results in <a href="#CD010844-fig-0004">Figure 4</a> and <a href="#CD010844-fig-0005">Figure 5</a>), and sensitivity analyses for risk of bias (open‐label delivery) are presented for the six‐month class analyses. </p> <div class="figure" id="CD010844-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="St George's Respiratory Questionnaire (SGRQ) change from baseline—six‐month and 12‐month class results." data-id="CD010844-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>St George's Respiratory Questionnaire (SGRQ) change from baseline—six‐month and 12‐month class results. </p> </div> </div> </div> <div class="figure" id="CD010844-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trough forced expiratory volume in one second (FEV1) change from baseline—six‐month and 12‐month class results." data-id="CD010844-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trough forced expiratory volume in one second (FEV<sub>1</sub>) change from baseline—six‐month and 12‐month class results. </p> </div> </div> </div> <section id="CD010844-sec-0092"> <h4 class="title">St George's Respiratory Questionnaire</h4> <p>Across six months and 12 months, 42 studies with 118 individual treatment nodes were included in the networks (n = 54,613). </p> <section id="CD010844-sec-0093"> <h5 class="title">Main analysis—six months</h5> <p>Eighteen treatments were compared over a total of 72 treatment arms in 25 studies (n = 27,024). Thirty‐nine pair‐wise comparisons were made, and the fixed‐effect model was preferred because statistical heterogeneity was not significant (DIC random = 214.9, fixed = 214.5). </p> <section id="CD010844-sec-0094"> <h6 class="title">Class effects</h6> <p><a href="#CD010844-tbl-0006">Table 6</a> shows each class effect relative to placebo (i.e. the combined treatment benefit over placebo), expressed as change from baseline. The classes are also ranked (mean and median) and are presented with estimates of the probability that each is the best class. <a href="#CD010844-fig-0004">Figure 4</a> displays class effects against the reference treatment (placebo), shown by the vertical dashed line on the right‐hand side of the graph. </p> <div class="table" id="CD010844-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">SGRQ class effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Sensitivity analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.70 to ‐2.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.66 to ‐3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.53 to ‐1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.58 to ‐2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.18 to ‐1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.93 to ‐1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.06 to ‐0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.99 to ‐0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>SGRQ = St George's Respiratory Questionnaire.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </div> <p>Combination LABA/ICS was the highest ranked treatment, with a mean improvement over placebo of 3.89 units (95% credible interval (CrI) ‐4.70 to ‐2.97). LAMAs and LABAs were ranked second and third, with mean differences of ‐2.63 (95% CrI ‐3.53 to ‐1.97) and ‐2.29 (95% CrI ‐3.18 to ‐1.53), respectively, but a large degree of overlap was noted between their credible intervals. Inhaled corticosteroids were the fourth ranked class but still showed a mean two‐unit benefit over placebo at six months (95% CrI ‐3.06 to ‐0.87). <a href="#CD010844-fig-0006">Figure 6</a> shows graphs of the probabilities that each class ranks in any one of the five possible positions. The median within‐class variance was 0.44 units (95% CrI 0.03 to 1.09). </p> <div class="figure" id="CD010844-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="St George's Respiratory Questionnaire (SGRQ) probability ranking diagrams—six months and 12 months." data-id="CD010844-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>St George's Respiratory Questionnaire (SGRQ) probability ranking diagrams—six months and 12 months. </p> </div> </div> </div> </section> <section id="CD010844-sec-0095"> <h6 class="title">Individual treatment effects</h6> <p>Effects relative to placebo are presented separately for each treatment in <a href="#CD010844-tbl-0007">Table 7</a>, along with ranks and estimates with and without the class model for comparison. The credible intervals for each treatment were wide and largely overlapping (for both ranks and mean differences from placebo). </p> <div class="table" id="CD010844-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">SGRQ individual treatment effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Rank (from class NWMA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> NWMA no class</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank (from class NWMA)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment (number daily doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form 12 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.60 to ‐0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.10 to ‐0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(10 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 300 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.63 to ‐1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.86 to ‐1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 150 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.95 to ‐1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.76 to ‐2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm 50 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.98 to ‐1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.27 to ‐1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(7 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 5 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.16 to ‐1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.20 to ‐1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 18 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.12 to ‐1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.33 to ‐1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 200 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.04 to ‐1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐6.14 to ‐1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.40 to ‐1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐6.94 to ‐2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gly 50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.42 to ‐1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.74 to ‐1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.82 to ‐0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.32 to 0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(7 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut 500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.07 to ‐0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.40 to ‐0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mom 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.51 to ‐1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.47 to ‐1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/160 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.91 to ‐3.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.99 to ‐2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/320 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.63 to ‐2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.39 to ‐2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐mom 12/200 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.82 to ‐2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐5.17 to ‐1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐mom 12/400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.72 to ‐2.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.81 to ‐1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm‐flut 50/500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.97 to ‐3.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐5.60 to ‐3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>SGRQ = St George's Respiratory Questionnaire.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </div> <p>Individual treatment effects of particular note within a class were associated with indacaterol and aclidinium for LABA and LAMA, respectively. Effects for both doses of each of these drugs were dampened by the class model in the six‐month SGRQ network (indacaterol by 0.72 and 0.92 for 300 mcg and 150 mcg, respectively, and aclidinium by 1.13 and 1.78 for 200 mcg and 400 mcg, respectively). Treatments of note for which estimates were inflated by fitting the class model were formoterol 12 mcg (by 0.64), budesonide 400 mcg (by 0.79) and formoterol/mometasone combination 2/400 mcg (by 0.66). </p> </section> </section> <section id="CD010844-sec-0096"> <h5 class="title">Additional analyses</h5> <section id="CD010844-sec-0097"> <h6 class="title">12 months</h6> <p>Nineteen treatments were compared in 24 studies, but a dose comparison of aclidinium made in <a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> was disconnected from the rest of the network. These treatments can be used in class analysis, as they “borrow” the class effect. The fixed‐effect model was preferred. </p> <p>In the class analysis (<a href="./appendices#CD010844-sec-0125">Appendix 4</a> and <a href="#CD010844-fig-0004">Figure 4</a>), LABA/ICS combinations remained the highest ranked at 12 months, with only a slightly smaller mean effect over placebo than at six months (‐3.60, 95% CrI ‐4.63 to ‐2.34). Compared with the six‐month analysis, LABA, LAMA and ICS showed more similar benefits over placebo at 12 months, ranging between ‐2.34 and ‐2.55, with similar credible intervals. Within‐class variance was slightly larger than in the six‐month analysis (median 0.53, 95% CrI 0.04 to 1.27). </p> <p>Individual treatment effects for the 12‐month analysis are presented in <a href="./appendices#CD010844-sec-0126">Appendix 5</a>. </p> </section> <section id="CD010844-sec-0098"> <h6 class="title">Sensitivity analysis—blinding</h6> <p><a href="#CD010844-tbl-0006">Table 6</a> shows how the six‐month effects were affected by removal of data at high risk of bias for blinding (see 'Effect vs placebo sensitivity analysis'). The difference between point estimates of LAMA over LABA was larger with less overlap in the credible intervals, and within‐class variance was smaller than in the main analysis (median 0.35, 95% CrI 0.02 to 0.98). Inconsistency associated with <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> was resolved by removing the open‐label tiotropium arm, but unexplained poor fit of three further trials remained (<a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>). As all open‐label arms removed were given tiotropium, it is possible that the expected treatment benefit over placebo in these studies was reduced by lack of blinding for these comparisons, which dampened the overall treatment effect within the LAMA class. </p> </section> </section> </section> <section id="CD010844-sec-0099"> <h4 class="title">Trough FEV<sub>1</sub> </h4> <p>Across six months and 12 months, 46 studies with 120 individual treatment nodes were included in the networks (n = 47,409). </p> <section id="CD010844-sec-0100"> <h5 class="title">Main analysis—six months</h5> <p>Twenty treatments were compared over a total of 82 treatment arms in 31 studies (n = 29,271). Forty‐one pair‐wise comparisons were made. The random‐effects model was preferred (DIC = 691), as the fixed‐effect model has very poor fit (DIC = 719.1). </p> <section id="CD010844-sec-0101"> <h6 class="title">Class effects</h6> <p><a href="#CD010844-tbl-0008">Table 8</a> shows each class effect relative to placebo. As for SGRQ, the classes are also ranked (mean and median) and are presented with estimates of the probability that each is the best. <a href="#CD010844-fig-0006">Figure 6</a> displays trough FEV<sub>1</sub> class effects (mL) compared with placebo. </p> <div class="table" id="CD010844-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">FEV1 class effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Sensitivity analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(100.60 to 164.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(98.93 to 165.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(81.78,124.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(79.01 to 126.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(71.98,127.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(70.41 to 130.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(33.06,96.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(31.23 to 97.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </div> <p>Results at six months showed a similar pattern to the SGRQ analysis. Combination LABA/ICS was the highest ranked treatment, with a mean improvement over placebo of 133.3 mL (95% CrI 100.6 to 164.0) after six months. As was the case for quality of life, LAMAs and LABAs were ranked second and third, with mean differences of 103.5 (95% CrI 81.8 to 124.9) and 99.4 (95% CrI 72.0 to 127.8), respectively, but again a large degree of overlap was noted between the credible intervals. Inhaled corticosteroids were the fourth ranked class but still showed a mean 65.4 mL benefit over placebo at six months (95% CrI 33.1 to 96.9). The median within‐class variance was 9.04 mL (95% CrI 0.41 to 34.85). <a href="#CD010844-fig-0007">Figure 7</a> shows graphs of the probabilities that each class ranks in any one of the five possible positions. </p> <div class="figure" id="CD010844-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forced expiratory volume in one second (FEV1) probability ranking diagrams—six months and 12 months." data-id="CD010844-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forced expiratory volume in one second (FEV<sub>1</sub>) probability ranking diagrams—six months and 12 months. </p> </div> </div> </div> </section> <section id="CD010844-sec-0102"> <h6 class="title">Individual treatment effects</h6> <p>Effects relative to placebo are presented separately for each treatment in <a href="#CD010844-tbl-0009">Table 9</a>, along with ranks and estimates with and without the class model for comparison. </p> <div class="table" id="CD010844-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">FEV1 individual treatment effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> NWMA no class</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank (from class NWMA)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment (number daily doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form 12 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(60.70 to 122.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(13.00 to 94.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 300 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(71.95 to 150.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(63.69 to 209.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 150 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(72.32 to 127.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(65.74 to 133.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm 50 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(73.39 to 130.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(75.96 to 149.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 5 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(81.87 to 131.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(73.82 to 145.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 10 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(79.80 to 142.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(62.88 to 175.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 18 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(85.54 to 125.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(82.93 to 129.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 200 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(59.06 to 123.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(9.47 to 107.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 200 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(65.20 to 127.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(11.81 to 134.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(80.93 to 143.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(45.06 to 168.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gly 50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(79.83 to 127.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(67.86 to 133.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(23.86 to 94.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐29.22 to 58.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(14 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud 750+ (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(14.75 to 99.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐95.77 to 91.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(12 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut 250 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(34.19 to 101.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(29.36 to 122.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(11 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut 500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(40.20 to 109.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(54.90 to 138.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(8 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/160 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(91.65 to 164.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(26.99 to 132.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/320 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(85.14 to 159.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(28.75 to 116.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm‐flut 50/250 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(106.20 to 182.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(116.20 to 226.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm‐flut 50/500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(104.40 to 172.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(104.10 to 197.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, bigger values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </div> <p>The class model affected individual treatment effects to a lesser extent in the FEV<sub>1</sub> network than in the SGRQ one, because less intra class variation was present. Several treatment effects that were higher than the class mean were dampened by the class model, including indacaterol 300 (by 34.6 mL) and salmeterol‐fluticasone 50/250 mcg combination therapy (by 33.3 mL). Effects for formoterol 12 mcg and both formoterol/budesonide combination doses were less favourable within their classes and were inflated by the class model (by 41.0 mL, and 50.3 and 54.5 mL, respectively). Although aclidinium was particularly effective in the SGRQ analysis, the relative effects for both lower doses on trough FEV<sub>1</sub> appeared less favourable than other members of the LAMA class (MD 59.3 and 74.8 mL without the class model compared with the overall class mean of 103.5). Within the ICS class, the two budesonide doses showed less benefit over placebo than the two fluticasone doses. However, credible intervals for the individual treatment groups were wide and overlapping. </p> </section> </section> <section id="CD010844-sec-0103"> <h5 class="title">Additional analyses</h5> <section id="CD010844-sec-0104"> <h6 class="title">12 months</h6> <p>Nineteen treatments were compared in 22 studies. As with the 12‐month SGRQ analysis, the dose comparison of aclidinium made in <a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> was disconnected from the rest of the network. The random‐effects model was preferred (DIC = 485.4), as the fixed‐effect model had very poor fit (DIC = 557.4). </p> <p>In the class analysis (<a href="./appendices#CD010844-sec-0127">Appendix 6</a> and <a href="#CD010844-fig-0006">Figure 6</a>), LABA/ICS remained the highest ranked treatment strategy, although the effect over placebo was lower than at six months (100 mL, 95% CrI 55.5 to 140.1). As with SGRQ, the benefit of LAMA over LABA was much less clear at 12 months, and their credible intervals showed a large degree of overlap with each other and with the LABA/ICS class. Within‐class variance was larger than in the six‐month analysis (median 18.02, 95% CrI 1.22 to 47.80). </p> <p>Individual treatment effects for the 12‐month analysis are presented in <a href="./appendices#CD010844-sec-0128">Appendix 7</a>. </p> </section> <section id="CD010844-sec-0105"> <h6 class="title">Sensitivity analysis—blinding</h6> <p><a href="#CD010844-tbl-0008">Table 8</a> shows how the six‐month effects were influenced by removal of data at high risk of bias for blinding. Within‐class variance was similar to that in the main analysis (median 10.49, 95% CrI 0.54 to 37.66). The effects were very similar with and without the open‐label data, unlike in the SGRQ analysis. This may reflect the nature of the two measurements, with SGRQ perhaps more susceptible to performance or detection bias than measures of lung function. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010844-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010844-sec-0106">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010844-sec-0156">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010844-sec-0106"></div> <section id="CD010844-sec-0107"> <h3 class="title" id="CD010844-sec-0107">Summary of main results</h3> <p>Evidence from good quality and similar trials supports LABA/ICS combination therapy as the highest ranking treatment strategy to improve quality of life and to benefit lung function in the included trials (mostly with participants whose FEV<sub>1</sub> was less than 50% predicted). Combination therapy gave an average benefit of 3.9 units over placebo at six months (95% CrI ‐4.70 to ‐2.97). LAMAs (MD ‐2.63, 95% CrI ‐3.53 to ‐1.97) were ranked second and LABAs ranked third at six months (MD ‐2.29, 95% CrI ‐3.18 to ‐1.53), especially when trials at high risk of bias were not included, but the difference between these classes was small, and a large degree of overlap was noted in their estimates. </p> <p>Combination LABA/ICS was the highest ranked class for trough FEV<sub>1</sub>, with a mean improvement over placebo of 133.3 mL at six months (95% CrI 100.6 to 164.0). As was the case for SGRQ, LAMAs ranked second (MD 103.5, 95% CrI 81.8 to 124.9) and LABAs ranked third (MD 99.4, 95% CrI 72.0 to 127.8) at six months; ICSs were the fourth ranking class (MD 65.4 mL, 95% CrI 33.1 to 96.9). </p> <p>For both outcomes, the effects of LABA and ICS monotherapies appeared to be additive at six months, but initial differences between treatment classes were less prominent after a year of treatment. </p> </section> <section id="CD010844-sec-0108"> <h3 class="title" id="CD010844-sec-0108">Overall completeness and applicability of evidence</h3> <p>The SGRQ analyses showed that combination LABA/ICS treatment had a mean difference over placebo in line with the minimal clinically important difference (MCID) of four units, and the point estimates and 95% confidence intervals of the other classes were lower than four units. However, it is not appropriate to imply that LABA/ICS provides a meaningful quality of life benefit while the other classes do not. A previous review demonstrated that a treatment that has a mean difference and 95% CI of lower than four units on the SGRQ can nevertheless lead to a significantly higher number of patients who reach a four‐unit change on the SGRQ in the treatment group than in the placebo group (<a href="./references#CD010844-bbs2-0173" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [Airways code: TIO6‐COP; DOI: 10.1002/14651858.CD009285] ">Karner 2012a</a>). For FEV<sub>1</sub>, with the exception of ICS monotherapy, treatment differences ranged from 99 to 133 mL, which is in keeping with the threshold of clinical significance suggested by <a href="./references#CD010844-bbs2-0150" title="CazzolaM , MacNeeW , MartinezFJ , RabeKF , FranciosiLG , BarnesPJ , et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal2008;31(2):416‐69. ">Cazzola 2008</a> (100 to 140 mL). </p> <p>National guidelines recommend the treatments included in this review (LABA, LAMA or LABA/ICS) over regular short‐acting medications for patients with exacerbations or persistent breathlessness (<a href="./references#CD010844-bbs2-0183" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 3 October 2013). ">NICE 2011</a>), otherwise referred to as those with moderate (stage II) or severe (stage III) COPD (<a href="./references#CD010844-bbs2-0166" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com (accessed 3 October 2013). ">GOLD</a>). <a href="./references#CD010844-bbs2-0183" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 3 October 2013). ">NICE 2011</a> recommends the addition of ICS in people who also have less than 50% predicted FEV<sub>1</sub>. By collating information about participants included in each of the included trials and assessing for transitivity, we were able to be clear about the types of patients to whom the conclusions of this review are likely to apply. Although some individual trials within the network included participants who exceeded or fell short of the criteria described in the guidelines, summary statistics suggest that participant groups in the trials fell into the moderate and severe categories, and most participants had an FEV<sub>1</sub> of less than 50% predicted. As a result, the evidence is not applicable to those with mild symptoms. Similarly, because of the common exclusion criteria in the trials related to co‐morbidities, and asthma in particular, these findings may not be relevant to some groups of patients. Finally, because the decision was made not to include some newer treatments and combination therapies in the network, class results may not be applicable to emerging treatments. </p> <p>To supplement the efficacy findings, we sought to identify evidence of cost‐effectiveness. As LABA/ICS was the most effective treatment for both outcomes and is likely to be the most costly treatment strategy in many settings, we sought to identify studies evaluating its cost‐effectiveness against other treatment options, and whether this varied across patients with varying levels of symptoms. Three recent studies based on reanalysis of clinical trials were found, all of which concluded that LABA/ICS is a cost‐effective treatment strategy for moderate to severe COPD (<a href="./references#CD010844-bbs2-0152" title="ChuckA , JacobsP , MayersI , MarciniukD . Cost‐effectiveness of combination therapy for chronic obstructive pulmonary disease. Canadian Respiratory Journal2008;15(8):437‐43. ">Chuck 2008</a>; <a href="./references#CD010844-bbs2-0162" title="EarnshawSR , WilsonMR , DalalAA , ChambersMG , JhingranP , StanfordR , et al. Cost‐effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respiratory Medicine2009;103(1):12‐21. ">Earnshaw 2007</a>; <a href="./references#CD010844-bbs2-0164" title="FattoreG , TorbicaA , MangoneM . Cost‐analysis of four treatment strategies in the management of moderate‐to‐severe COPD: an application of non‐parametric bootstrap [Italian]. Pharmacoeconomics Italian Research Articles2005;7(2):135‐43. ">Fattore 2005</a>). Evidence suggests that the reduction in healthcare resource use associated with LABA/ICS compared with placebo or with the single components outweighs the additional cost of combination inhalers. One study (<a href="./references#CD010844-bbs2-0152" title="ChuckA , JacobsP , MayersI , MarciniukD . Cost‐effectiveness of combination therapy for chronic obstructive pulmonary disease. Canadian Respiratory Journal2008;15(8):437‐43. ">Chuck 2008</a>) showed that this benefit was more prominent in patients with severe disease ($39,000 per quality‐adjusted life‐year (QALY)) than in those with moderate and severe disease combined ($47,500 per QALY). </p> <p><a href="./references#CD010844-bbs2-0173" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [Airways code: TIO6‐COP; DOI: 10.1002/14651858.CD009285] ">Karner 2012a</a> raised concerns about the safety of tiotropium when delivered via the Respimat inhaler, arising from indirect comparisons between trials using Respimat and Handihaler devices. Published evidence from a very large trial that randomly assigned participants to tiotropium via Respimat or Handihaler does not show a higher risk of mortality when the Respimat inhaler was used (<a href="./references#CD010844-bbs2-0196" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT Disse B , et al. Tiotropium Respimat inhaler and the risk of death in COPD. New England Journal of Medicine Vol. 369, issue 16:1491‐501. ">Wise 2013</a>). </p> </section> <section id="CD010844-sec-0109"> <h3 class="title" id="CD010844-sec-0109">Quality of the evidence</h3> <p>We assessed the methodological quality of all included studies and concluded that risk of bias was generally low across the five domains. Uncertainties associated with allocation concealment and outcome reporting could have been resolved in part by contacting trial authors, but because most of the included studies were already included in other Cochrane reviews, it is unlikely that this would have substantially increased our confidence in the results, especially because a vast majority of trials were sponsored by manufacturers with whom we have confirmed the adequacy of methods in the past. The sensitivity analysis removing comparisons at high risk of performance or detection bias further increased our confidence in the findings. </p> <p>The transitivity assumption was upheld across both outcome data sets. The trials were similar in their conduct, and when discrepancies were noted (especially with allowed co‐medications and inhaler devices), these did not appear to differ systematically between nodes or classes. Because of the nature of indirect comparisons, the similarity in baseline characteristics and methodology justified analysing the trials in a network and increased the applicability of the results. Participants randomly assigned to the LABA/ICS arms had somewhat more impaired lung function than those assigned to the other classes, but this did not translate into any real differences when transitivity across pairwise comparisons between classes was assessed. The presence of several large multi‐arm trials allowed us to combine the indirect evidence obtained via common comparators with a good quantity of head‐to‐head data within and across classes, and this increased the reliability of the network findings. </p> </section> <section id="CD010844-sec-0110"> <h3 class="title" id="CD010844-sec-0110">Potential biases in the review process</h3> <p>By including studies from existing Cochrane reviews and performing additional electronic searches to both update the data and fill gaps not covered by other reviews, it is likely that the relevant literature has been covered by this review. Around 80% of the studies included in this review had already been included in another Cochrane review and so had already been assessed for risk of bias and had data extracted by two review authors. We were not able to contact study authors to ask for additional data, but we were able to extract and include data for the vast majority of studies that measured the outcomes. </p> </section> <section id="CD010844-sec-0111"> <h3 class="title" id="CD010844-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>Several recent network meta‐analyses of treatments for COPD have been published with varying inclusion criteria and outcomes. <a href="./references#CD010844-bbs2-0157" title="DecramerML , HananiaNA , Lotvall , JO , YawnBP . The safety of long‐acting β2‐agonistsin the treatment of stable chronic obstructive pulmonary disease. International Journal of COPD2013;8:53‐64. ">Decramer 2013</a> and <a href="./references#CD010844-bbs2-0161" title="DongY , LinH , ShauW , WuY , ChangC , LaiM . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68:48‐56. ">Dong 2013</a> focused on safety outcomes and included only longer‐term studies of at least six months' duration. <a href="./references#CD010844-bbs2-0157" title="DecramerML , HananiaNA , Lotvall , JO , YawnBP . The safety of long‐acting β2‐agonistsin the treatment of stable chronic obstructive pulmonary disease. International Journal of COPD2013;8:53‐64. ">Decramer 2013</a> included only LABA therapy and found no association between LABA and increased COPD‐related adverse events or mortality. In addition, "LABA treatment was generally associated with significant or numerical reductions in COPD exacerbations compared with placebo," which is in keeping with the effects of LABA shown in our review. <a href="./references#CD010844-bbs2-0161" title="DongY , LinH , ShauW , WuY , ChangC , LaiM . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68:48‐56. ">Dong 2013</a> had very similar inclusion criteria to those of our network and focused on mortality. Alongside our findings on the additive efficacy of the LABA/ICS combination, the <a href="./references#CD010844-bbs2-0161" title="DongY , LinH , ShauW , WuY , ChangC , LaiM . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68:48‐56. ">Dong 2013</a> network provided evidence that "LABA‐ICS was associated with the lowest risk of death among all treatments," and that "no excess risk was noted for tiotropium HandiHaler or LABA." These reviews provide comparative evidence relating to safety, especially <a href="./references#CD010844-bbs2-0161" title="DongY , LinH , ShauW , WuY , ChangC , LaiM . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease:systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68:48‐56. ">Dong 2013</a>, which included a similar network of treatments and listed similar trial inclusion criteria. </p> <p><a href="./references#CD010844-bbs2-0155" title="CopeS , ZhangJ , WilliamsJ , JansenJP . Efficacy of once‐daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta‐analysis. BMC Pulmonary Medicine2012;12:29. ">Cope 2012</a> included a similar list of COPD treatments in their network and assessed efficacy using similar outcomes on shorter time scales (SGRQ and lung function at three months). Although their focus was on indacaterol, their conclusions regarding its efficacy in comparison with older LABAs were in keeping with our findings. Similarly, a subsequent network meta‐analysis including glycopyrronium but not including LABA/ICS combinations (<a href="./references#CD010844-bbs2-0156" title="CopeS , DonohueJF , JansenJP , KraemerM , Capkun‐NiggliG , BaldwinM , et al. Comparative efficacy of long‐acting bronchodilators for COPD—a network meta‐analysis. Respiratory Research2013;14:100. ">Cope 2013</a>) concluded that indacaterol, glycopyrronium and tiotropium were the most favourable bronchodilators (based on evidence for SGRQ and FEV<sub>1</sub> at three months and at six months). Although these treatments were amongst the best LABAs and LAMAs, differences between the two network meta‐analyses (i.e. the list of included treatments, time points and analysis model) explain the discrepancies in conclusions. </p> <p>With regard to other important outcomes, a network meta‐analysis by <a href="./references#CD010844-bbs2-0184" title="PuhanMA , BachmannLM , KleijnenJ , ter RietG , KesselsAG . Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta‐analysis. BMC Medicine2009;7:2. ">Puhan 2009</a> focusing on exacerbations and the same treatment classes found "no evidence that one single inhaled drug regimen is more effective than another in reducing exacerbations." The authors also concluded that "inhaled corticosteroids when added to long‐acting beta‐agonists reduce exacerbations only in patients with COPD with FEV<sub>1</sub> ≤ 40%." Because of issues of network connectivity, we did not consider it reasonable to analyse our data sets with baseline severity as a co‐variate, but <a href="./references#CD010844-bbs2-0184" title="PuhanMA , BachmannLM , KleijnenJ , ter RietG , KesselsAG . Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta‐analysis. BMC Medicine2009;7:2. ">Puhan 2009</a> raises the question of whether certain treatments may be more beneficial or may cause different adverse effects for particular patient groups. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010844-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram.  aAll 58 studies identified in the review search were also identified in the electronic database search.  Abbreviations: CDSR = Cochrane Database of Systematic Reviews." data-id="CD010844-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.<br/> <sup>a</sup>All 58 studies identified in the review search were also identified in the electronic database search.<br/> Abbreviations: CDSR = Cochrane Database of Systematic Reviews. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010844-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Network structures for both outcomes at six months." data-id="CD010844-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Network structures for both outcomes at six months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010844-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010844-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010844-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="St George's Respiratory Questionnaire (SGRQ) change from baseline—six‐month and 12‐month class results." data-id="CD010844-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>St George's Respiratory Questionnaire (SGRQ) change from baseline—six‐month and 12‐month class results. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010844-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trough forced expiratory volume in one second (FEV1) change from baseline—six‐month and 12‐month class results." data-id="CD010844-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trough forced expiratory volume in one second (FEV<sub>1</sub>) change from baseline—six‐month and 12‐month class results. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010844-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="St George's Respiratory Questionnaire (SGRQ) probability ranking diagrams—six months and 12 months." data-id="CD010844-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>St George's Respiratory Questionnaire (SGRQ) probability ranking diagrams—six months and 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010844-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/urn:x-wiley:14651858:media:CD010844:CD010844-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_t/tCD010844-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forced expiratory volume in one second (FEV1) probability ranking diagrams—six months and 12 months." data-id="CD010844-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forced expiratory volume in one second (FEV<sub>1</sub>) probability ranking diagrams—six months and 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/media/CDSR/CD010844/image_n/nCD010844-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010844-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">All included studies—summary characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weeks</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arms included<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% male</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% pred FEV<sub>1b</sub> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pack‐years<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0002" title="JonesP , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPE , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64(Suppl IV):A168 [P213]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. ">ACCLAIM 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0003" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLaim/COPD ii: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM II 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0004" title="AnzuetoA , FergusonG , FeldmanG , SelbertA , ChinskyK , EmmettA , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 with salmeterol on COPD exacerbations [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D40. AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A1502 [Poster #K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):1‐9. GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg BID with salmeterol DISKUS 50mcg BID on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). ">Anzueto 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>indacaterol, tiotropium, glycopyrronium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0009" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0014" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms and delays exacerbations in patients with COPD previously maintained on ICS [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [155]. ">Calverley 2003b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mometasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mometasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, formoterol/budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0018" title="AstraZeneca . A 6‐month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with chronic obstructive pulmonary disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD‐037‐0709. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012). BogdanM , ElirazA , McKinnonC , NihlenU , RadeczkyE , SolimanS , et al. Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1578. CampbellM , ElirazA , JohanssonG , TornlingG , NihlénU , BengtssonT , et al. Formoterol for maintenance and as‐needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine2005;99(12):1511‐20. CampbellM , RabeKF , AnderssonA . Formoterol turbuhaler for maintenance and as‐needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 Poster 417. ElirazA , BengtssonT , BogdanM , CoenenPDM , JohansonG , OsmanilevD , et al. Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1580. ">Campbell 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0019" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology &amp; Therapeutics2005;18(2):75‐81. CasaburiR , MahlerDA , JonesPW , WannerA , SanPG , ZuWallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5s. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD conference; November 14‐15; Arlington, Virginia. 2003:Abstract no: 1189. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (Spiriva), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics2007;8(2):123‐35. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerSJPW , SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. Zu WallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW , et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ">Casaburi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0020" title="ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal [Revue canadienne de pneumologie]2007;14(8):465‐72. ">Chan 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, mometasone, formoterol/mometasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>indacaterol (2), tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0026" title="DusserD , BravoML , IaconoP , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. DusserD , BravoML , IaconoP , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , BravoML , IanonoP , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , VielK , BravoML , IaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , IanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0028" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multicenter trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. DalalAA , StCharlesM , PetersenHV , RobertsMH , BlanchetteCM , Manavi‐ZieverinkK . Cost‐effectiveness of combination fluticasone propionate‐salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2010;5:179‐87. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respiratory Medicine2008;102(8):1099‐108. SCO40043G . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS Â® 250/50mcg bid with salmeterol DISKUS Â® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/study/SCO40043#ps (accessed 3 March 2014). [] ">Ferguson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aclidinium (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>glycopyrronium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>glycopyrronium, tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0034" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). KardosP , WenckerM . Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1944. KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(2):144‐9. VogelmeierC , WenckerM , GlaabT , KardosP . Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QOL) more than salmeterol (SAL) alone in COPD [Abstract]. Norwegian Thoracic Society 42nd Nordic Lung Conference; June 9‐11; Trondheim. 2005; Vol. 15, issue Suppl 22. VogelmeierCF , WenckerM , GlaabTH , KardosP . Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A110 [Poster J8]. ">Kardos 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone (2), salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0037" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary diseases [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1584. ">Laptseva 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, fluticasone, salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, tiotropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0040" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, Orlando. 2004:A84. NiewoehnerDE , LokhnyginaY , RiceK , KuschnerWG , SharafkhanehA , SarosiGA , et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest2007;131(1):20‐8. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJADJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0042" title="OzolD , AysanT , AytemurZ , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin‐8 levels and cell percentage in stable chronic obstructive pulmonary disease patients. European Respiratory Journal2001;18(Suppl 33):212s. OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0043" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 mcg daily with placebo in chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [GSK: FLIT97] GlaxoSmithKline . A multicentre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). [GSK: FLTB3054] PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre double‐blind, placebo‐controlled study investigating the effect of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. European Respiratory Journal1997;10 Suppl 25:427S. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre, randomised, double‐blind, placebo‐controlled trial of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. ">Paggiaro 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0045" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. Powriej , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661s [P3839]. ">Powrie 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (med)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0050" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250 mcg, with salmeterol 50 mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO100470</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol/fluticasone, fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0053" title="SenderovitzT , MaltbaekN , PedersenB , NorgaardM , NielsenC , VestboJ , et al. Prednisolone followed by inhaled budesonide vs placebo in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(Suppl 25):257S. SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide/formoterol (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium (OL), glycopyrronium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, budesonide, formoterol/budesonide (3), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (med)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, mometasone, formoterol/mometasone (2), placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0062" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):96 [240]. ">To 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, indacaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0063" title="TonneiAB , BravoML , BrunM , TonnelAB . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonneiAB , PerezT , GrosboisJM , BravoML , BrunM , TonnelAB . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1934. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease2008;3(2):301‐10. ">Tonnel 2008 [TIPHON]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0064" title="SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus PRN salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1589. ">Trooster 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0065" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJ , HoogstedenHC , PrinsJB . Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A798. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , MulderPGH , BogaardJM , HoogstedenHC . Inhaled fluticasone propionate (FP) has a significant effect on FEV1 of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxyJOUR species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>formoterol, tiotropium, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol, tiotropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tiotropium, salmeterol/fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0070" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com (accessed 6 March 2014). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2006;130(4 Suppl):182s. ZhengJP , YangL , WuYM , ChenP , WenZG , HuangWJ , et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest2007;132(6):1756‐63. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50 µg/fluticasone propionate 500 µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology (Carlton, Vic.)2006;11(Suppl 5):A150 [PS‐3‐9]. ">Zheng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salmeterol/fluticasone, placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0071" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012;28(2):257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):5225A. ">Zhong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>budesonide, formoterol/budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nr</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Numbers in parentheses indicate multiple doses of the same treatment. </p> <p><sup>b</sup>Age, % predicted FEV<sub>1</sub> and pack‐years smoked are reported as means unless otherwise stated. </p> <p>bid = twice daily.</p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> <p>nr = not reported.</p> <p>PBO = placebo inhaler.</p> <p>qd = once daily.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">All included studies—summary characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">SGRQ network composition and transitivity assessmenta </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % FEV<sub>1c</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Packs<sup>d</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13,808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22,406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.9</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Summary population data are for all study comparisons excluding those made in the 29 studies that could not be included in either the six‐month or the 12‐month SGRQ network. </p> <p><sup>b</sup>Age = mean years. </p> <p><sup>c</sup>% FEV<sub>1</sub> = mean percentage predicted FEV<sub>1</sub>. </p> <p><sup>d</sup>Packs = mean pack‐years. </p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> <p>SGRQ = St George's Respiratory Questionnaire.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">SGRQ network composition and transitivity assessmenta </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">FEV1 network composition and transitivity assessmenta </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> %FEV<sub>1c</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Packs<sup>d</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23,111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS vs Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS vs LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.5</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Summary population data are for all study comparisons excluding those made in the 23 studies that could not be included in either the six‐month or the 12‐month FEV<sub>1</sub> network; all doses are given in micrograms. </p> <p><sup>b</sup>Age = mean years. </p> <p><sup>c</sup>% FEV<sub>1</sub> = mean percentage predicted FEV<sub>1</sub>. </p> <p><sup>d</sup>Packs = mean pack‐years. </p> <p>FEV1 = forced expiratory volume in one second.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">FEV1 network composition and transitivity assessmenta </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Distribution of studies by individual treatment node</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment node mcg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>LABA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol 12 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; <a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a>; </p> <p><a href="./references#CD010844-bbs2-0018" title="AstraZeneca . A 6‐month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with chronic obstructive pulmonary disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD‐037‐0709. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012). BogdanM , ElirazA , McKinnonC , NihlenU , RadeczkyE , SolimanS , et al. Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1578. CampbellM , ElirazA , JohanssonG , TornlingG , NihlénU , BengtssonT , et al. Formoterol for maintenance and as‐needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine2005;99(12):1511‐20. CampbellM , RabeKF , AnderssonA . Formoterol turbuhaler for maintenance and as‐needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 Poster 417. ElirazA , BengtssonT , BogdanM , CoenenPDM , JohansonG , OsmanilevD , et al. Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1580. ">Campbell 2005</a>; <a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; <a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a>; </p> <p><a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; </p> <p><a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a><sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol 24 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indacaterol 300 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indacaterol 600 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indacaterol 150 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol 50 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0004" title="AnzuetoA , FergusonG , FeldmanG , SelbertA , ChinskyK , EmmettA , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 with salmeterol on COPD exacerbations [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D40. AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A1502 [Poster #K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):1‐9. GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg BID with salmeterol DISKUS 50mcg BID on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). ">Anzueto 2009</a>; <a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a>; <a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; </p> <p><a href="./references#CD010844-bbs2-0028" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multicenter trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. DalalAA , StCharlesM , PetersenHV , RobertsMH , BlanchetteCM , Manavi‐ZieverinkK . Cost‐effectiveness of combination fluticasone propionate‐salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2010;5:179‐87. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respiratory Medicine2008;102(8):1099‐108. SCO40043G . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS Â® 250/50mcg bid with salmeterol DISKUS Â® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/study/SCO40043#ps (accessed 3 March 2014). [] ">Ferguson 2008</a>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0034" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). KardosP , WenckerM . Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1944. KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(2):144‐9. VogelmeierC , WenckerM , GlaabT , KardosP . Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QOL) more than salmeterol (SAL) alone in COPD [Abstract]. Norwegian Thoracic Society 42nd Nordic Lung Conference; June 9‐11; Trondheim. 2005; Vol. 15, issue Suppl 22. VogelmeierCF , WenckerM , GlaabTH , KardosP . Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A110 [Poster J8]. ">Kardos 2007</a>; <a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0050" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250 mcg, with salmeterol 50 mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO100470</a>; <a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a>; </p> <p><a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a><sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>LAMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 5 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a>; <a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a>; <a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 10 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a>; <a href="./references#CD010844-bbs2-0019" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology &amp; Therapeutics2005;18(2):75‐81. CasaburiR , MahlerDA , JonesPW , WannerA , SanPG , ZuWallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5s. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD conference; November 14‐15; Arlington, Virginia. 2003:Abstract no: 1189. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (Spiriva), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics2007;8(2):123‐35. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerSJPW , SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. Zu WallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW , et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ">Casaburi 2002</a>; <a href="./references#CD010844-bbs2-0020" title="ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal [Revue canadienne de pneumologie]2007;14(8):465‐72. ">Chan 2007</a>;<br/> <a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0026" title="DusserD , BravoML , IaconoP , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. DusserD , BravoML , IaconoP , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , BravoML , IanonoP , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , VielK , BravoML , IaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , IanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a><sup>a</sup>;<br/> <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0039" title="MahmudAM , GuptaDK , KhanAS , HassanR , HossainA , RahmanM , et al. Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A211. ">Mahmud 2007</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0040" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, Orlando. 2004:A84. NiewoehnerDE , LokhnyginaY , RiceK , KuschnerWG , SharafkhanehA , SarosiGA , et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest2007;131(1):20‐8. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJADJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0045" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. Powriej , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661s [P3839]. ">Powrie 2007</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>;<br/> <a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a>; <a href="./references#CD010844-bbs2-0063" title="TonneiAB , BravoML , BrunM , TonnelAB . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonneiAB , PerezT , GrosboisJM , BravoML , BrunM , TonnelAB . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1934. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease2008;3(2):301‐10. ">Tonnel 2008 [TIPHON]</a>; <a href="./references#CD010844-bbs2-0064" title="SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus PRN salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1589. ">Trooster 2011</a><sup>a</sup>;<br/> <a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0068" title="BeehKM , HedererB , GlaabT , MüllerA , Rutten‐van MoelkenM , KestenS , et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease2009;4(1):119‐25. BeehKM , VogelmeierC , Rutten‐van MölkenM , RabeKF , GlaabT , et al. Tiotropium vs salmeterol in GOLD II and maintenance‐naive COPD patients: subgroup analyses of POET‐COPD™ trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:20s [P251]. FabbriLM , VogelmeierC , Rutten‐van MölkenMPMH , RabeKF , GlaabT , RuhmkorfF , et al. Baseline characteristics of patients with frequent exacerbations in the POET‐COPD trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:49s [405]. [] GlaabT , VogelmeierC , SchmidtH , Rutten‐van MölkenM , BeehKM , RabeK , et al. Seasonal distribution of exacerbations in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A3726. [] HoogendoornM , AlMJ , BeehKM , BowlesD , Graf von der SchulenburgJM , LungershausenJ , et al. Cost‐effectiveness of tiotropium versus salmeterol: the POET‐COPD trial. European Respiratory Journal2013;41(3):556‐64. [] RabeKF , FabbriLM , VogelmeierC , KöglerH , SchmidtH , BeehKM , et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest2013;143(3):711‐9. Rutten‐van MölkenMPMH , FabbriLM , RabeKF , KöglerH , GlaabT , SchmidtH , et al. Do exacerbation outcomes in the POET‐COPD trial differ between regions? [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:82s [P559]. [] VogelmeierC , FabbriLM , RabeKF , BeehKM , SchmidtH , MetzdorfN , et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. Respiratory Medicine2013;107(1):75‐83. VogelmeierC , HedererB , GlaabT , SchmidtH , Rutten‐van MölkenMP , BeehKM , et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine2011;364(12):1093‐103. VogelmeierC , RabeK , BeehKM , GlaabT , SchmidtH , Rutten‐van MolkenM , et al. Tiotropium reduces exacerbations versus salmeterol irrespective of baseline ICS treatment in the POET‐COPD study [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1600. VogelmeierCF , BeehKM , Rutten‐van MolkenM , GlaabT , SchmidtH , HedererB . Baseline characteristics according to gender in a large exacerbations trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4495. ">Vogelmeier 2011 [POET]</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aclidinium bromide 200 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0002" title="JonesP , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPE , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64(Suppl IV):A168 [P213]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. ">ACCLAIM 2009</a>; <a href="./references#CD010844-bbs2-0003" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLaim/COPD ii: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM II 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aclidinium bromide 200 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a>; <a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aclidinium bromide 400 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a>; <a href="./references#CD010844-bbs2-0030" title="GelbA , TashkinD , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term safety of twice‐daily aclidinium bromide in COPD patients: a one‐year, double‐blind study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:376s [P2118]. GelbAF , MakeBJ , TashkinDP , ZhongX , GarciaGE , CaractaC . Long‐term efficacy and safety of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2256. TashkinD , GelbA , MakeB , ZhongX , Garcia GilE , CaractaC . Long‐term efficacy of twice‐daily aclidinium bromide in COPD patients: a one‐year study [Abstract]. European Respiratory Society 22nd Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2893]. ">Gelb 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycopyrronium bromide 50 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a>; <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 320‐400 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0037" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary diseases [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1584. ">Laptseva 2002</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0042" title="OzolD , AysanT , AytemurZ , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin‐8 levels and cell percentage in stable chronic obstructive pulmonary disease patients. European Respiratory Journal2001;18(Suppl 33):212s. OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0053" title="SenderovitzT , MaltbaekN , PedersenB , NorgaardM , NielsenC , VestboJ , et al. Prednisolone followed by inhaled budesonide vs placebo in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(Suppl 25):257S. SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; </p> <p><a href="./references#CD010844-bbs2-0071" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012;28(2):257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):5225A. ">Zhong 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide 750‐1000 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0009" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a>; <a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone 250 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone 500 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a>; <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>;<br/> <a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a>; <a href="./references#CD010844-bbs2-0043" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 mcg daily with placebo in chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [GSK: FLIT97] GlaxoSmithKline . A multicentre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). [GSK: FLTB3054] PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre double‐blind, placebo‐controlled study investigating the effect of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. European Respiratory Journal1997;10 Suppl 25:427S. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre, randomised, double‐blind, placebo‐controlled trial of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. ">Paggiaro 1998</a>; <a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a>;<br/> <a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0065" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJ , HoogstedenHC , PrinsJB . Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A798. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , MulderPGH , BogaardJM , HoogstedenHC . Inhaled fluticasone propionate (FP) has a significant effect on FEV1 of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxyJOUR species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a><sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mometasone 400 bid or 800 qd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0014" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms and delays exacerbations in patients with COPD previously maintained on ICS [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [155]. ">Calverley 2003b</a>; <a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a>; <a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>LABA/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/bud 12/160 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; <a href="./references#CD010844-bbs2-0071" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012;28(2):257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):5225A. ">Zhong 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/bud 12/320 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; </p> <p><a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/mom 12/200 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol/mom 12/400 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol/flut 50/250 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0004" title="AnzuetoA , FergusonG , FeldmanG , SelbertA , ChinskyK , EmmettA , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 with salmeterol on COPD exacerbations [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D40. AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A1502 [Poster #K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):1‐9. GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg BID with salmeterol DISKUS 50mcg BID on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). ">Anzueto 2009</a>; <a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD010844-bbs2-0027" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih Chinese Journal of Tuberculosis &amp; Respiratory Diseases2008;31(11):811‐4. ">Fang 2008</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a>; <a href="./references#CD010844-bbs2-0041" title="OharJA , CraterG , EmmettA , FerroT , MorrisA , RaphiouI , et al. Effects of fluticasone propionate/salmeterol combination 250/50mcg bid (advair diskus) vs. salmeterol 50mcg bid (serevent diskus) on chronic obstructive pulmonary disease (COPD) exacerbation rate, following acute exacerbation or hospitalization. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2439. ">Ohar 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol/flut 50/500 bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; </p> <p><a href="./references#CD010844-bbs2-0028" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multicenter trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. DalalAA , StCharlesM , PetersenHV , RobertsMH , BlanchetteCM , Manavi‐ZieverinkK . Cost‐effectiveness of combination fluticasone propionate‐salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2010;5:179‐87. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respiratory Medicine2008;102(8):1099‐108. SCO40043G . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS Â® 250/50mcg bid with salmeterol DISKUS Â® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/study/SCO40043#ps (accessed 3 March 2014). [] ">Ferguson 2008</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a>; <a href="./references#CD010844-bbs2-0050" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250 mcg, with salmeterol 50 mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO100470</a>; <a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0052" title="ZuWallackR , FogartyC , GiesselG , McClung , LocantoreN , RaphiouI , et al. Effect of fluticasone propionate/salmeterol combination on change in bone mineral density in subjects with COPD [Abstract]. Chest2008;134(4):104002s. ">SCO40041</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0069" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest2011;139(3):505‐12. GlaxoSmithKline . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations—the INSPIRE study methodology. Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of salmeterol/fluticasone propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology (Carlton, Vic.)2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine2008;177(1):19‐26. ">Wedzicha 2008 [INSPIRE]</a>; <a href="./references#CD010844-bbs2-0070" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com (accessed 6 March 2014). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2006;130(4 Suppl):182s. ZhengJP , YangL , WuYM , ChenP , WenZG , HuangWJ , et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest2007;132(6):1756‐63. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50 µg/fluticasone propionate 500 µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology (Carlton, Vic.)2006;11(Suppl 5):A150 [PS‐3‐9]. ">Zheng 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PBO</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo inhaler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0001" title="AbrahamsR , Moroni‐ZentgrafP , RamsdellJ , SchmidtH , JosephE , KarpelJ . Safety and efficacy of the once‐daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine2013;107(6):854‐62. AbrahamsR , RamsdellJ , Moroni‐ZentgrafP , SchmidtH , JosephB , KarpelJ . Comparison of BEA2180 to tiotropium and placebo via respimat in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Respirology2012;17(Suppl 2):46 [292]. ">Abrahams 2013</a>; <a href="./references#CD010844-bbs2-0002" title="JonesP , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. Efficacy and safety of aclidinium bromide, a novel long‐acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2022]. JonesPE , ChanezP , AgustiA , MagnussenH , FabbriL , CaractaC , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax2009;64(Suppl IV):A168 [P213]. JonesPW , AgustiA , ChanezP , MagnussenH , FabbriL , MaroniJ , et al. A phase III study evaluating aclidinium bromide, a novel long‐acting antimuscarinic, in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6180 [Poster #207]. ">ACCLAIM 2009</a>; <a href="./references#CD010844-bbs2-0003" title="JonesPW , RennardSI , AgustiA , ChanezP , MagnussenH , FabbriL , et al. Efficacy and safety of once‐daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research2011;12:55. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . ACCLaim/COPD ii: efficacy and safety of aclidinium bromide; a novel long‐acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[E4351]. RennardS , DonohueJ , BatemanE , GrossN , Garcia GilE , CaractaC . Efficacy and safety of the novel, long‐acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6178 [Poster #205]. ">ACCLAIM II 2009</a>; <a href="./references#CD010844-bbs2-0005" title="AgustiA , JonesPW , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Journal2011;38(55):149s [P874]. BatemanED , SinghD , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal2011;38(55):730s [P4005]. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , DeMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health‐care utilization and the EXACT diary card [Abstract]. Chest2011;140(4):529A. JonesP , AgustiA , BatemanE , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study [Abstract]. Chest2011;140(4):547A. JonesP , BatemanE , SinghD , AgustiA , LamarcaR , DeMiquelG , et al. Attain: efficacy and safety of twice‐daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2011;140(4):975A. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A6350. JonesPW , AgustiA , BatemanED , SinghD , LamarcaR , deMiquelG , et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIN [Abstract]. European Respiratory Journal2011;38(55):150s [P877]. JonesPW , ChuecosF , LamarcaR , SinghD , AgustiA , BatemanED , et al. Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine2013;187:A6072. JonesPW , SinghD , AgustiA , BatemanED , LamarcaR , deMiquelG , et al. Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Journal2012;40(Suppl 56):9s [195]. JonesPW , SinghD , BatemanED , AgustiA , LamarcaR , deMiquelG , et al. Efficacy and safety of twice‐daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal2012;40(4):830‐6. SinghD , BatemanED , JonesPW , AgustiA , LamarcaR , deMiquelG , et al. The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal2011;38(55):149s [P875]. SinghD , JonesPW , BatemanED , AgustiA , LamarcaR , DeMiquelG , et al. Attain: twice‐daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax2011;66(Suppl 4):A171 [P255]. ">ATTAIN 2011</a>; </p> <p><a href="./references#CD010844-bbs2-0006" title="BatemanED , TashkinD , SiafakasN , DahlR , TowseL , MasseyD , et al. A one‐year trial of tiotropium Respimat plus usual therapy in COPD patients. Respiratory Medicine2010;104(10):1460‐72. ">Bateman 2010a</a>; <a href="./references#CD010844-bbs2-0007" title="BatemanE , SinghD , SmithD , DisseB , TowseL , MasseyD , et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1‐year randomized studies. International Journal of Chronic Obstructive Pulmonary Disease2010;5:197‐208. HodderR , PaviaD , LeeA , BatemanE . Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat Soft Mist Inhaler in COPD. International Journal of Chronic Obstructive Pulmonary Disease2011;6(1):245‐51. ">Bateman 2010b</a>; <a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a>; <a href="./references#CD010844-bbs2-0009" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a>; </p> <p><a href="./references#CD010844-bbs2-0010" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. BatemanED , JenkinsC , KorduckiL , KestonS . Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. BrusascoV , HodderR , MiravitllesM , KorduckiL , TowseL , KestenS . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax2003;58(5):399‐404. BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. BrusascoV , MenjogeSS , KestenS . Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006:A110 [Poster J10]. BrusascoV , ThompsonP , VinckenW , LeeA , TowseL , WitekTJ . Improvement of dyspnea following six months of treatment with tiotropium but not with salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. DonohueJF . Alterations in bronchodilator effectiveness over six months with tiotropium and salmeterol. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A227. DonohueJF , MenjogeS , KestenS . Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine2003;97(9):1014‐20. DonohueJF , vanNoordJA , BatemanED , LangleySJ , LeeA , WitekTJ , et al. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest2002;122(1):47‐55. [0012‐3692] DonohueJF , vanNoordJA , LangleySJ , LeeA , KestenS , TowseLJ . Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. European Respiratory Journal2001;18(Suppl 33):26s. GuntherK , LeeA , KestenS , TowseL . Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; Jun 7‐9; Amsterdam. 2002:p112. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics: Health Economics in Prevention and Care2007;8(2):123‐35. ">Brusasco 2003</a>; <a href="./references#CD010844-bbs2-0011" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The Isolde study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A491. CalverleyP , SpencerS , WillitsL , BurgePS , JonesP . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A271. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW , Group IO. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350‐6. CalverleyPMA , SpencerS , WilletsL , BurgePS , JonesPW . Inhaled corticosteroids prevent treatment failure in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A271. D'UrzoAD . Withdrawal of treatment in the ISOLDE study. Chest2004;125(6):2368. JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JonesPW , WillitsLR , BurgePS , CalverleyPM , Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. ScottPH , BaleGA , BurgePS . COPD rapid decliners have better FEV1 response to inhaled fluticasone propionate 500 �g bd than slower decliners [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A581. ScottPH , BaleGA , BurgePS . Inhaled fluticasone propionate in COPD: better response in those with more rapid FEV1 decline. European Respiratory Journal2000;16(Suppl 31):276s. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW , ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. ">Burge 2000 [ISOLDE]</a>; <a href="./references#CD010844-bbs2-0013" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH , et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. CalverleyPMA . Effect of Budesonide/Formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. CalverleyPMA , OlssonH , the Symbicort International CSG, Symbicort International CSG, CalverleyPA , Symbicort International CG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , SthalE , JonesPW , StåhlE . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. CalverlyPMA , CsekeZ , PetersonS , CalverleyPMA . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P436]. CalverlyPMA , KunaP , OlssonH , CalverleyPMA . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1587. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International conference, May 21‐26, 2004, Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando. 2003:B024 [Poster 419]. JonesPWSE , JonesPW , StåhlE , StahlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D46. LofdahlCG , AndreasssonE , SvenssonK , EricssonA , AndreassonE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. PharmacoEconomics2005;23(4):365‐75. ">Calverley 2003a</a>; <a href="./references#CD010844-bbs2-0012" title="CalverleyP , PauwelsR , VestboJ . Erratum. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9369):1660. CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyP , PauwelsRA , JonesPW , AndersonJA , VestbosJ . The severity of airways obstruction as a determinant of treatment response in COPD. International Journal of COPD2006;1(3):209‐18. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideNB , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol/fluticasone propionate combination in differing severities of COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:A035 Poster D50. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A226. ClaverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. American Journal of Respiratory and Critical Care Medicine2002;165(8 Suppl):A226. EdinHM , PriceMJ , WireP , LeeB , ChangC , DarkenP , et al. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://www.gsk‐clinicalstudyregister.com/study/SFCB3024#rs (accessed 11 February 2014). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal2004;24(Suppl 48):291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A111. KhamisRYRRK , KhamisRY , RajakulasingamRK . Combined salmeterol and fluticasone for COPD. Lancet2003;361(9369):1652; author reply 1652‐3. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsRA , CalverleyPMA , VestboJ , JonesP , PrideNB , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 Poster 215. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideNB , GulsvikA , et al. Absence of JOURder susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP , TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPA , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99thInternational Conference; May 16‐21; Seattle. 2003:A035 Poster D48. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP , et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 [TRISTAN]</a>; </p> <p><a href="./references#CD010844-bbs2-0014" title="CalverleyP , PauwelsR , NieminemM , StryszakP , StaudingerH , LeeT . Once daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms and delays exacerbations in patients with COPD previously maintained on ICS [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [155]. ">Calverley 2003b</a>; <a href="./references#CD010844-bbs2-0015" title="AllegraL . TORCH study: an invitation to clinical considerations. Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. [] CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11(Suppll 5):A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves survival in COPD over three years [Abstract]. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E311]. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesP , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22(Suppl 45):578s. [] CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. Respirology2006;11(Suppl 5):A140 [O‐9‐2]. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28(Suppl 50):34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A320 [Poster 323]. CelliB , EmmettA , CraterG , KalbergC , CelliD . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):764s [4395]. CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:[A763]. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CorhayJL , LouisR . [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]. [French]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference, May 18‐23, San Francisco. San Francisco, California, USA, 2007:[A763]. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009;136(6):1456‐65. GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks [SCO100540]. http://www.gsk‐clinicalstudyregister.com/study/100540?study_ids=SCO100540#rs (accessed 3 March 2014). GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS Accuhaler, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [] GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500 mcg bd, salmeterol 50 mcg bd and fluticasone propionate 500 mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. [] JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A839 [Poster 603]. [] JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesP , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN , et al. Trans‐regional validity of the SGRQ in the TORCH survival study [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A122 [Poster J79]. [] JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. American Thoracic Society International Conference; May 19‐24; San Diego. 2006:A122, Poster J79. [] JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years [Abstract]. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJACB , FergusonGT , JenkinsCR , YatesJC , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice (1995)2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE, et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. San Francisco, California, USA, 2007:Poster #A41. NCT . A multicenter, randomized, double‐blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment. ClinicalTrials.gov2000. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 3 March 2014). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. http://www.gsk‐clinicalstudyregister.com/study/SCO30003#ps (accessed 3 March 2014). [] SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: the TORCH study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , AndersonJA , CalverleyPMA , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCHSG , CalverleyP , CelliB , FergusonG , JenkinsC , et al. The TORCH (towards a revolution in COPD health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:A120. [] WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT , AndersonJA , et al. Reliability of cause specific mortality adjudication in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A120 [Poster J68]. [] ">Calverley 2007 [TORCH]</a>; <a href="./references#CD010844-bbs2-0016" title="CalverleyPM , RennardS , NelsonHS , KarpelJP , AbbateEH , StryszakP , et al. One‐year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research2008;9:73. NelsonH , KarpelJP , StaudingerH , BusseWW . Mometasone furoate dry powder inhaler (MF‐DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD [Abstract]. Chest2004;126(4 Suppl):709S‐c, 710. ">Calverley 2008</a>; <a href="./references#CD010844-bbs2-0017" title="CalverleyPMA , KunaP , MonsóE , CostantiniM , PetruzzelliS , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104(12):1858‐68. ">Calverley 2010</a>; </p> <p><a href="./references#CD010844-bbs2-0018" title="AstraZeneca . A 6‐month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with chronic obstructive pulmonary disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD‐037‐0709. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012). BogdanM , ElirazA , McKinnonC , NihlenU , RadeczkyE , SolimanS , et al. Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1578. CampbellM , ElirazA , JohanssonG , TornlingG , NihlénU , BengtssonT , et al. Formoterol for maintenance and as‐needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine2005;99(12):1511‐20. CampbellM , RabeKF , AnderssonA . Formoterol turbuhaler for maintenance and as‐needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 Poster 417. ElirazA , BengtssonT , BogdanM , CoenenPDM , JohansonG , OsmanilevD , et al. Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1580. ">Campbell 2005</a>; <a href="./references#CD010844-bbs2-0019" title="AdamsSG , AnzuetoA , BriggsDD , MenjogeSS , KestenS . Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respiratory Medicine2006;100(9):1495‐503. AnzuetoA , KestenS . Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C47 Poster F81. AnzuetoA , TashkinD , MenjogeS , KestenS . One‐year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulmonary Pharmacology &amp; Therapeutics2005;18(2):75‐81. CasaburiR , MahlerDA , JonesPW , WannerA , SanPG , ZuWallackRL , et al. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal2002;19(2):217‐24. FriedmanM , BellT , MenjogeSS , AntonS , KochP . Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD. European Respiratory Journal2001;18(Suppl 33):5s. KestenS , MenjogeS . Can patient demographics be used to predict future choices for antibiotics, steroids, or both for exacerbations of COPD? [Abstract]. National COPD conference; November 14‐15; Arlington, Virginia. 2003:Abstract no: 1189. MahlerDA , MontnerP , BrazinskySA , GoodwinB , MenjogeSS , WitekTJ . Tiotropium (Spiriva), a new long‐acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. Rutten‐van MölkenMP , OostenbrinkJB , MiravitllesM , MonzBU . Modelling the 5‐year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. European Journal of Health Economics2007;8(2):123‐35. SerbyCW . Impact of tiotropium on COPD exacerbations: 1‐Yr studies versus placebo or ipratropium. European Respiratory Review2002;12(82):16‐7. SpencerS . Decline in health status over one year is eliminated by tiotropium. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. SpencerSJPW , SpencerS , JonesPW . Short‐term changes in health status with tiotropium predict long‐term changes in health status [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1611. TashkinD , KestenS . Long‐term treatment benefits with tiotropium in COPD patients with and without short‐term bronchodilator responses. Chest2003;123(5):1441‐9. Zu WallackR , JonesPW , KotchA , GoodwinB , MenjogeSS , SerbyCW , et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A892. ">Casaburi 2002</a>; <a href="./references#CD010844-bbs2-0020" title="ChanCK , MaltaisF , SigouinC , HaddonJM , FordGT , Group SS, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal [Revue canadienne de pneumologie]2007;14(8):465‐72. ">Chan 2007</a>; <a href="./references#CD010844-bbs2-0021" title="CooperCB , AbrazadoM , LeggD , KestenS . Development and implementation of treadmill exercise testing protocols in COPD. International Journal of Chronic Obstructive Pulmonary Disease2010;5:375‐85. CooperCB , CelliB , WiseRA , JardimJR , LeggD , GuoJ , et al. 'Treadmill endurance during 2 years' treatment with tiotropium in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4586. CooperCB , CelliBR , WiseR , deBrito JardimJR , GuoJ , et al. Relationship between quality of life and exercise endurance in a long‐term study of tiotropium in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A1534. ">Cooper 2010</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0022" title="BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily improves dyspnoea and BODE index in COPD patients: a 52‐week study [Abstract]. European Respiratory Society Annual Congress; Sep 12‐15; Vienna. 2009:[P2026]. BuhlR , PietersW , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily reduces COPD exacerbations over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6185 [Poster #212]. ChungF , KornmannO , JackD , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4359]. ChungKF , KornmannO , JackD , OwenR , KramerB , HigginsM , et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:A4546 [Poster #J56]. DahlR , ChungKF , BuhlR , MagnussenH , NonikovV , JackD , et al. Efficacy of a new once‐daily long‐acting inhaled beta2‐agonist indacaterol versus twice‐daily formoterol in COPD. Thorax2010;65(6):473‐9. DahlR , KolmanP , JackD , BleasdaleP , OwenR , HigginsM , et al. Bronchodilator therapy with indacaterol once‐daily in COPD: a 52‐week comparison with formoterol [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4350]. DahlR , KolmanP , JackD , OwenR , KramerB , HigginsM . Indacaterol once‐daily provides sustained 24‐h bronchodilation over 52 weeks of treatment in COPD [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A4545 [Poster #J55]. MagnussenH , PaggiaroP , JackD , OwenR , HigginsM , KramerB , et al. Bronchodilator treatment with indacaterol once‐daily vs formoterol twice‐daily in COPD: a 52‐week study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6184 [Poster #211]. MagnussenH , VerkindreC , JackD , JadayelD , OwenR , HigginsM , et al. Indacaterol once‐daily is equally effective dosed either in the evening or morning in COPD patients [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4361]. NonikovV , VerkindreC , JackD , BleasdaleP , OwenR , KramerB , et al. Indacaterol once‐daily improves symptom control in COPD patients: a 52‐week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2024]. NonikovV , VerkindreC , JackD , OwenR , HigginsM , KramerB . Indacaterol once‐daily reduces days of poor control in COPD over 52 weeks of treatment [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A6190 [Poster #218]. ">Dahl 2010</a>; </p> <p><a href="./references#CD010844-bbs2-0023" title="Dal NegroR , MichelettoC , TrevisonF , TognellsS , PomariC , SpencerS , et al. Salmeterol &amp; fluticasone 50 µg/250 µg bid vs salmeterol 50 µg bid and vs placebo in the long‐term treatment of COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. Dal NegroRW , PomariC , TognellaS , MichelettoC , Dal NegroR . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD010844-bbs2-0024" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 Suppl):AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:57‐71. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of COPD2012;7:73‐86. ">Doherty 2012</a>; <a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a>; <a href="./references#CD010844-bbs2-0026" title="DusserD , BravoML , IaconoP , LaconoP . The effect of tiotropium on exacerbations and airflow in patients with COPD. European Respiratory Journal2006;27(3):547‐55. DusserD , BravoML , IaconoP , LaconoP . Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , BravoML , IanonoP , LanonoP . Tiotropium COPD exacerbations the MISTRAL study [Abstract]. European Respiratory Journal2004;24(Suppl 48):513s. DusserD , VielK , BravoML , IaconoP . Tiotropium reduces moderate‐to‐severe exacerbations in COPD patients irrespective of concomitant use of inhaled corticosteroids (ICS) [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H6]. DusserD , VielK , RouyrreN , IanconoP . Tiotropium reduces COPD exacerbations requiring treatment with systemic corticosteroids, antibiotics, or hospitalizations [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A603 [Poster H5]. ">Dusser 2006</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0029" title="EdenHM , PriceMJ , JenkinsR , DarkenP , HorstmanD . Fluticasone propionate improves quality of life in patients with COPD. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A643. RennardS , BaileyW , TashkinD , AbrahamsR , HorstmanD , HoS , et al. Improvements in airflow &amp; dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250mcg &amp; 500mcg for 24 weeks via the diskus(r) inhaler [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. ">FLTA3025</a>; </p> <p><a href="./references#CD010844-bbs2-0031" title="D'UrzoA , FergusonGT , vanNoordJA , HirataK , MartinC , HortonR , et al. Efficacy and safety of once‐daily NVA237 in patients with moderate‐to‐severe COPD: the GLOW1 trial. Respiratory Research2011;12:156. D'UrzoA , VanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P252. D'UrzoT , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial [Abstract]. Thorax2011;66(Suppl 4):P253. D’UrzoA , FergusonG , KatoM , AtisS , MartinC , AlagappanVKT , et al. NVA237 once daily provides rapid, clinically meaningful and sustained 24‐h bronchodilation in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:147s [P866]. [GLOW1: NCT01005901] D’UrzoA , FergusonG , MartinC , AlagappanVKT , BanerjiD , LuY , et al. NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24‐hours: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 133. D’UrzoA , FergusonG , MartinC , LuY , BanerjiD , OverendT . NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:608s [3427]. D’UrzoA , vanNoordJA , MartinC , HortonR , BanerjiD , LuY , et al. Once‐daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial [Abstract]. 6th IPCRG World Conference; Apr 25‐28; Edinburgh. 2012:Abstract 134. KatoM , D'UrzoA , MartinC , BanerjiD , LuY , OverendT . NVA237 once daily improves symptoms and reduces exacerbations of COPD and associated hospitalizations: the GLOW1 trial [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):105 [634]. vanNoordJA , HirataK , D’UrzoA , MartinC , HortonR , LuY , et al. NVA237 once daily improves dyspnea and health‐related quality of life (HRQoL) in patients with COPD: the GLOW1 trial [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:148s [P867]. ">GLOW1 2011</a>; <a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a>; <a href="./references#CD010844-bbs2-0033" title="GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). HananiaNA . Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. American Journal of Respiratory Medicine2002;1(4):284. HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP , et al. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. 68th Annual Chest Meeting; Nov 2–7; San Diego. 2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination[Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P434]. KnobilK , YatesJ , HorstmanD , DarkenP , WireP . Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease. [Abstract]. 68th Annual Chest Meeting; Nov 2‐7; San Diego. 2002:P288. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD conference; Nov 14‐15; Arlington. 2003:Abstract no: 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract No: [P429]. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD , et al. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22 Suppl 45:Abstract No: [P438]. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 308]. ">Hanania 2003</a>; <a href="./references#CD010844-bbs2-0035" title="KornmannO , DahlR , CentanniS , DograA , OwenR , LassenC , et al. Once‐daily indacaterol versus twice‐daily salmeterol for COPD: a placebo‐controlled comparison. European Respiratory Journal2011;37(2):273‐9. KornmannO , LuthraA , OwenR , LassenC , KramerB . Once‐daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26‐week placebo‐controlled study [Abstract]. Chest2009;136(4):152S. ">Kornmann 2011</a>; <a href="./references#CD010844-bbs2-0036" title="GosmanMME , LapperreTS , Snoeck‐StrobandJB , JansenDF , KerstjensHAM , HiemstraPS , et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A111 [Poster J15]. KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One2013;8(5):e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. LapperreTS , Snoeck‐StrobandJB , GosmanMM , SontJK , JansenDF , RabeKF , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone (FP) with or without salmeterol (S) on bronchial inflammation in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A39. Snoeck‐StrobandJB , KerstjensHAM , LapperreTS , BoezenHM , ThiadensHA , tenHackenNHT , et al. Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long‐term inhaled corticosteroids (ICS) on FEV1‐decline in patients with mild‐to‐moderate COPD [Abstract]. European Respiratory Society 20th Annual Congress; Sep 18‐22; Barcelona. 2010:[P4015]. Snoeck‐StrobandJB , LapperreTS , BoezenHM , SontJK , ThiadensHA , TimensW , et al. Predicting the benefits by inhaled steroids on the accelerated decline of FEV1 in COD [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A519[#705]. Snoeck‐StrobandJB , LapperreTS , GosmanMME , AssendelftWJJ , BoezenHM , tenHackenNHT , et al. Patient‐reported clinical control and peak‐flow:effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long‐acting B2‐agonists (LABA) in moderately severe COPD [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2923 [Poster #G37]. Snoek‐StrobandJB , LapperreTS , GosmanMM , SontJK , JansenDF , StolkJ , et al. Effects of 30 vs 6 months treatment with inhaled fluticasone propionate (FP) with or without salmeterol (S) on FEV1 PC20 and health status in COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A38. ">Lapperre 2009</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0037" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary diseases [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1584. ">Laptseva 2002</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0038" title="FergusonG , Funck‐BrentanoC , FischerT , DarkenP , TroyS , ComptonC , et al. Cardiovascular safety of salmeterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine2002;165(Suppl 8):A228. FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. GlaxoSmithKline . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). LittnerM , YatesJ , FischerT , HorstmanD , WireP . Improvements in FEV1 and symptoms in poorly‐reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™ inhaler. European Respiratory Journal2001;18(Suppl 33):176s. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. MahlerDA , WongE , GiesselG , CliffordD , ChangC , YatesJ , et al. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A279. SpencerM , WireP , LeeB , ChangC , DarkenP , HortsmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. European Respiratory Journal2003;22(Suppl 45):Abstract P438. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. European Respiratory Journal2004;24(Suppl 48):290s. ">Mahler 2002</a>; <a href="./references#CD010844-bbs2-0040" title="Anonymous . Tiotropium reduces exacerbations in COPD. Pharmaceutical Journal2004;272(7302):696. KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. NiewoehnerD , Gonzalez‐RothiR , ShigeokaJ , KorduckiL , CassinoC , KestenS , et al. Reduced COPD exacerbations in patients without first‐dose peak FEV increases 15% with tiotropium [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 319]. NiewoehnerD , RiceK , CoteC , KorduckiL , CassinoC , KestenS . Characteristics of COPD and response to once‐daily tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A43] [Poster: F41]. NiewoehnerD , RiceK , CoteC , PaulsonD , CooperJA , KorduckiL , et al. Reduced COPD exacerbations and associated health care utilization with once‐daily tiotropium (TIO) in the VA medical system [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, Orlando. 2004:A84. NiewoehnerDE , LokhnyginaY , RiceK , KuschnerWG , SharafkhanehA , SarosiGA , et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest2007;131(1):20‐8. NiewoehnerDE , RiceK , CassinoC , LeimerI , KestenS . Reductions in COPD exacerbations with tiotropium in African Americans in the VA medical system [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A51. NiewoehnerDE , RiceK , CoteC , PaulsonD , CooperJADJr , KorduckiL , et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once‐daily inhaled anticholinergic bronchodilator: a randomized trial. Annals of Internal Medicine2005;143(5):317‐26. RiceKL , LeimerI , KestenS , NiewoehnerDE . Responses to tiotropium in African‐American and Caucasian patients with chronic obstructive pulmonary disease. Translational Research2008;152(2):88‐94. ">Niewoehner 2005</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0042" title="OzolD , AysanT , AytemurZ , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin‐8 levels and cell percentage in stable chronic obstructive pulmonary disease patients. European Respiratory Journal2001;18(Suppl 33):212s. OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a>; <a href="./references#CD010844-bbs2-0043" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 mcg daily with placebo in chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/ (accessed 3 March 2014). [GSK: FLIT97] GlaxoSmithKline . A multicentre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). [GSK: FLTB3054] PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre double‐blind, placebo‐controlled study investigating the effect of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. European Respiratory Journal1997;10 Suppl 25:427S. PaggiaroPL , DahleR , BakranI , HollingworthK , EfthimiouJ . A multicentre, randomised, double‐blind, placebo‐controlled trial of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. ">Paggiaro 1998</a>; </p> <p><a href="./references#CD010844-bbs2-0044" title="JohnellO , PauwelsR , LöfdahlCG , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). European Respiratory Journal2002;19(6):1058‐63. LieskerJJ , van derVeldeV , MeysmanM , VinckekW , WollmerP , HanssonL , et al. The effects of formoterol on exercise capacity in COPD. European Respiratory Society 9th Annual Congress; Oct 9‐13; Madrid. 1999:[P2511]. LöfdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. NoppenM , VinckenW . Effects of high‐dose inhaled fluticasone propionate (FP) on cellular and solute composition in bronchial (Brl) and bronchoalveolar (BAL) lavage fluid in COPD: a placebo controlled, double‐blind study. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A803. PauwelsRA , LöfdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.[see comment]. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LöfdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0045" title="PowrieD , WilkinsonT , DonaldsonG , VielK , JonesP , ScrineK , et al. The effect of tiotropium on diary based exacerbation frequency in COPD [Abstract]. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A604 [Poster H11]. PowrieDJ , DonaldsonGC , WilkinsonTM , JonesP , VielK , KestenS , et al. Tiotropium reduces exacerbations and common colds in patients with COPD [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #A50. PowrieDJ , WilkinsonTMA , DonaldsonGC , JonesP , ScrineK , VielK , et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. European Respiratory Journal2007;30(3):472‐8. Powriej , WilkinsonM , DonaldsonC , WedzichaA . Tiotropium reduces subjectively reported sputum production in COPD. European Respiratory Journal2006;28(Suppl 50):661s [P3839]. ">Powrie 2007</a>; <a href="./references#CD010844-bbs2-0046" title="RenkemaTE , KerstjensHA , SchoutenJP , VonkJM , KoëterGH , PostmaDS . The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clinical and Experimental Allergy1998;28(10):1210‐8. RenkemaTE , SchoutenJP , KoëterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. ">Renkema 1996</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0047" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):468A. NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. RennardSI , TashkinDP , MartinP , GoldmanM , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (pMDI) on exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A1513 [Poster #K65]. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103001s. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103003s. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010;138(4):863A. ">Rennard 2009</a>; <a href="./references#CD010844-bbs2-0048" title="AmgottTR , KristufekP , LevineB , ByrneA , TillD . Effect of inhaled formoterol and oral slow‐release theophylline on peak expiratory flow and symptoms in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A582. KristufekP , AmgottTR , LevineB , ByrneA , ColacchioC . Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow‐release theophylline in patients with COPD. American Journal of Respiratory and Critical Care Medicine2000;161(Suppl 3):A489. KristufekP , LevineB , Della CioppaG , ByrneA , TillD . Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. European Respiratory Journal2001;18(Suppl 33):514s. KristufekP , LevineB , TillD , ByrneA . Inhaled formoterol (foradil(r)) improves lung function in patients with both reversible and poorly reversible COPD [abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A280. RossiA , KristufekP , LevineBE , ThomsonMH , TillD , KottakisJ , et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow‐release theophylline in the treatment of COPD. Chest2002;121(4):1058‐69. ">Rossi 2002</a>; <a href="./references#CD010844-bbs2-0049" title="ChavannesN , SchermerT , WoultersEFM , FolgeringH , AkkermansR , MetsemakersJ , et al. Demographic and clinical determinants of response to N‐acetylcysteine versus fluticasone in mild to moderate COPD in primary care: the COOPT study [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1356. ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of Chronic Obstructive Pulmonary Disease2009;4:431‐6. ChavannesNH , SchermerTRJ , WoutersEFM , vanWeelC , vanSchayckCP . Treatment of COPD in general practice: the COOPT study. European Respiratory Journal2001;18(Suppl 33):348s. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. VanWeelC , SchermerT . Quality of life is not an indicator of COPD severity. Huisarts en Wetenschap2011;54(6):294‐7. ">Schermer 2009</a>; </p> <p><a href="./references#CD010844-bbs2-0051" title="GlaxoSmithKline . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs Bd and fluticasone propionate 250 µg two puffs Bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SCO30002</a>; <a href="./references#CD010844-bbs2-0053" title="SenderovitzT , MaltbaekN , PedersenB , NorgaardM , NielsenC , VestboJ , et al. Prednisolone followed by inhaled budesonide vs placebo in chronic obstructive pulmonary disease. European Respiratory Journal1997;10(Suppl 25):257S. SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a>; <a href="./references#CD010844-bbs2-0054" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD2011;8(1):2‐7. ShakerSB , StavngaardT , StoelB , DirksenA . The effect of inhaled corticosteroids on CT‐lung density in current smokers with COPD [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[A92] [Poster: 814]. ">Shaker 2009</a>; <a href="./references#CD010844-bbs2-0055" title="SharafkhanehA , SouthardJ , GoldmanM , UryniakT , MartinUJ . Long‐term effect of budesonide/formoterol pressurized metered‐dose inhaler on exacerbations and pulmonary function in patients with chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1599. SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on chronic obstructive pulmonary disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. SouthardJG , SharafkhanehA , GoldmanM , UryniakT , MartinUJ . Long‐term tolerability of budesonide/formoterol pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease and a history of exacerbations [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1597. ">Sharafkhaneh 2012</a>; <a href="./references#CD010844-bbs2-0056" title="GlaxoSmithKline . Multicentre, randomised, parallel group, placebo‐controlled, double‐blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/ (accessed 6 March 2014). ">SLMF4010</a>; </p> <p><a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a>; <a href="./references#CD010844-bbs2-0058" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZeneca . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). [AstraZeneca: SD‐039‐0629] BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. [] CalverleyP , Pauwels DaggerR , LofdahlCG , SvenssonK , HiJT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPM , SzafranskiW , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1917. [] Calverley PMA (on behalf of the Symbicort® study group). Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57(Suppl III):iii44. [] CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22(Suppl 45):P435. [] CampbellLMSW , CampellLW , SzafranskiW , CampbellL , CampbellLM . Budesonide/formoterol in a single inhaler (symbicort(r)) reduces severe exacerbations in patients with moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1575. EgedeFMG , EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1574. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th international conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. [] JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1613. KorsgaardJSR , KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1577. LangePSC , LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1‐year study [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1573. LofdahlC G , LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. [] MilanowskiJNS , MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P1576. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. SzafranskiW , RamirezA , PetersonS . Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society 12th Annual Congress; Sep 14‐18; Stockholm. 2002:abstract nr: P2453. ">Szafranski 2003</a>; <a href="./references#CD010844-bbs2-0059" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg &amp; 80/4.5 mcg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. http://www.astrazenecaclinicaltrials.com/ (accessed 6 March 2014). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012;142(2):320‐8. [] BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of beta2‐adrenergic receptor gene polymorphism gly16arg on response to budesonide/formoterol pressurized metered‐dose inhaler in chronic obstructive pulmonary disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A4086. [] CelliBR , TashkinDP , RennardSI , McElhattanJ , MartinUJ . Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine2011;105(8):1176‐88. [] NelsonHS , TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105002s. [] TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68:1975‐2000. ">Tashkin 2008 [SHINE]</a>; <a href="./references#CD010844-bbs2-0060" title="AntoniuSA . UPLIFT study: the effects of long‐term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2009;10(4):719‐22. BoehringerIngelheim . A randomized, double‐blind, placebo‐controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD). www.trials.boehringer‐ingelheim.com (accessed 3 March 2014). [] BraidoF . UPLIFT study: the results and their implications. Multidisciplinary Respiratory Medicine2009;4(Suppl 1):6s‐12s. BuhlR , WelteT , VogelmeierC , GillissenA , VoshaarT , KoglerH , et al. Early treatment of COPD with tiotropium. [German]. Pneumologie (Stuttgart, Germany)2012;66(10):589‐95. CelliB , DecramerM , KestenS , LiuD , MehraS , TashkinDP , et al. Mortality in the 4‐year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(10):948‐55. CelliB , DecramerM , TashkinD , CassinoC , BurkhartD , KestenS . Frequency of acute flow and volume responses to bronchodilator administration in patients with COPD [Abstract]. European Respiratory Journal2007;30(Suppl 51):525s [3163]. CelliB , DecramerM , TashkinDP , BukhartD , KestenS , CassinoC . Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #923. CelliB , KestenS , LystigT , TashkinDP , DecramerM . Long‐term changes in inspiratory capacity: an analysis from the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4482. [] CelliB , TashkinD , DecramerM , BurkhartD , CassinoC , KestenS . Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators. European Respiratory Journal2005;26(Suppl 49):716s. [] CelliBR , DecramerM , LystigT , KestenS , TashkinDP . Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research2012;13:66. CorhayJL , LouisR . The UPLIFT study (Understanding Potential Long‐term Impacts on Function with Tiotropium). Revue Medicale de Liege2009;64(1):52‐7. DecramerM , CelliB , BurkhartD , KestenS , MehraS , LiuD , et al. The effect of tiotropium on COPD GOLD stage II during the four‐year UPLIFT trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:A2466. DecramerM , CelliB , KestenS , LiuD , MenjogeS , SennS , et al. Statistical approaches to analysis of exacerbations in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1527. DecramerM , CelliB , KestenS , LystigT , MehraS , TashkinDP , et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. [see comment]. Lancet2009;374(9696):1171‐8. DecramerM , CelliB , TashkinDP , BurkhartD , KestenS , CassinoC . Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial. European Respiratory Journal2006;28(Suppl 50):526s. [] DecramerM , CelliB , TashkinDP , PauwelsRA , BurkhartD , CassinoC , et al. Clinical trial design considerations in assessing long‐term functional impacts of tiotropium in COPD: the UPLIFT trial. Journal of Chronic Obstructive Pulmonary Disease2004;1(2):303‐12. DecramerM , KestenS , CelliB , TashkinDP . How much lift to the UPLIFT study? ‐ Authors' reply. Lancet2010;375(9710):198. DecramerM , MolenberghsG , LiuD , CelliB , KestenS , LystigT , et al. Premature discontinuation during the UPLIFT study. Respiratory Medicine2011;105(10):1523‐30. DecramerM , PauwelsR , CelliB , TashkinD , BurkhartD , CassinoC , et al. Effectiveness of a spirometric quality assurance program in a large‐scale global COPD trial (UPLIFT). European Respiratory Journal2004;24(Suppl 48):32s. [] DecramerM , TashkinD , CelliB , FranceschinaJ , FioriL . Use of regular feedback on spirometry testing in a long‐term multinational COPD trial [Abstract]. American Thoracic Society International Conference; May 16‐21; Toronto. 2008:Poster #D79. [] FernandezL , KestenS , LiuD , DecramerM , TashkinD , CelliB , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial [Abstract]. Congress of the Asian Pacific Society of Respirology; Nov 22‐25; Manila. 2010. FukuchiY , FernandezL , KuoHP , MahayiddinA , CelliB , DecramerM , et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (Carlton, Vic.)2011;16(5):825‐35. HalpinD , DecramerM , CelliB , MartinA , LeimerI , MetzdorfN , et al. Effectiveness of tiotropium in low‐risk patients according to new GOLD severity grading [Abstract]. European Respiratory Journal2012;40(Suppl 56):392s [P2190]. HalpinDG , DecramerM , CelliB , KestenS , LiuD , TashkinDP . Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease2012;7:653‐61. HalpinDM , DecramerM , CelliB , KestenS , LeimerI , TashkinDP . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4‐year UPLIFT trial. Lung2011;189(4):261‐8. HananiaN , KestenS , CelliB , DecramerM , SharafkhanehA , LystigT , et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4353]. [] HananiaNA , SharafkhanehA , CelliB , DecramerM , LystigT , KestenS , et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research2011;12(1):6. HettleR , WoutersH , AyresJ , GaniR , KellyS , LionM , et al. Cost‐utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine2012;106(12):1722‐33. InoueH , AsaiY . UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study. Respiration and Circulation2009;57(8):813‐8. JanssensW , LiuD , KestenS , TashkinDP , CelliBR , DecramerM . Spirometry in UPLIFT®: quality and reproducibility over time [Abstract]. European Respiratory Society 21st Annual Congress; Sep 24‐28; Amsterdam. 2011; Vol. 38, issue 55:638s [P3567]. [] JanssensW , LiuY , LiuD , KestenS , TashkinDP , CelliBR , et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT). Respiratory Medicine2013;107(9):1409‐16. [] KestenS , CelliB , DecramerM , LiuD , TashkinD . Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. Respiratory Research2011;12:129. McGarveyL , MagderSA , LiuD , KestenS , ManuelR , NiewoehnerDE . A comparison of the classification of cause of death between site investigators and a mortality adjudication committee in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5916. McGarveyLP , MagderS , BurkhartD , KestenS , LiuD , ManuelRC , et al. Cause‐specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations. Respiratory Medicine2012;106(4):515‐21. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD in young patients: a pre‐specified analysis of the four‐year trial of tiotropium (UPLIFT). Respiratory Medicine2010;104(11):1659‐67. MoriceAH , CelliB , KestenS , LystigT , TashkinD , DecramerM . COPD patients under 50 years of age: 4‐year follow‐up in the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A12 [46]. [] OsztovitsJ , FeherJ . Safety of tiotropium therapy in chronic obstructive lung diseases (COPD). [Hungarian]. Orvosi Hetilap2010;151(18):749‐50. PaggiaroP , RossiA . 'Prince Charming'? Some considerations about the decline of FEV1 and on data from UPLIFT study. Rassegna di Patologia dell'Apparato Respiratorio2009;24(5):278‐86. Rodriguez Gonzalez‐MoroJM , LuceroS , deLucas RamosP . The UPLIFT study: future perspectives. [Spanish]. Archivos de Bronconeumologia2008;44(Suppl 2):39‐48. Rutten‐van MolkenM , OostenbrinkJ , MonzB . EQ‐5D discriminates between COPD patients of different severity. European Respiratory Journal2005;26(Suppl 49):470s. [] Rutten‐van MölkenMP , OostenbrinkJB , TashkinDP , BurkhartD , MonzBU . Does quality of life of COPD patients as measured by the JOUReric EuroQol five‐dimension questionnaire differentiate between COPD severity stages?. Chest2006;130(4):1117‐28. TashkinD , CelliB , DecramerM , BurkhartD , KestenS , CassinoC . Comorbid conditions reported in patients with COPD recruited into a global clinical trial (UPLIFT) [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 4203. TashkinD , CelliB , DecramerM , PaulwelsR , BurkhartD , KestenS . Regional patterns in the characteristics of patients recruited into a long‐term global clinical trial in COPD (UPLIFT) [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B46] [Poster: J126]. [] TashkinD , CelliB , KestenS , LystigT , DecramerM . Effect of tiotropium in men and women with COPD: results of the 4‐year UPLIFT trial. Respiratory Medicine2010;104(10):1495‐504. TashkinD , CelliB , LystigT , KestenS , DecramerM . Efficacy of tiotropium in COPD patients with FEV1: 60% participating in the UPLIFT trial [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18‐22. 2010:[P1186]. TashkinD , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Revista Portuguesa de Pneumologia2009;15(1):137‐40. TashkinDP . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT trial. [Review] [51 refs]. Expert Review of Respiratory Medicine2010;4(3):279‐89. [] TashkinDP , CelliB , BurkhartD , KestenS , LiuD , MehraS , et al. Long‐term efficacy of tiotropium in continuing smokers vs sustained ex‐smokers in the UPLIFT trial [Abstract]. American Thoracic Society International JOURerence, May 15‐20, San Diego. 2009:A6175 [Poster #201]. TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. TashkinDP , CelliB , KestenS , LiuD , DecramerM . Reduced reporting of respiratory failure in the UPLIFT(R) trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A4483. TashkinDP , CelliB , KestenS , LystigT , MehraS , DecramerM . Long‐term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal2010;35(2):287‐94. [] TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. [] TashkinDP , CelliBR , DecramerM , LystigT , LiuD , KestenS . Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD2012;9(3):289‐96. TashkinDP , CelliBR , KestenS , LiuD , DecramerM . Cardiovascular adverse events according to GOLD stage in the UPLIFT trial [Abstract]. Chest2009;136(4):52S‐g. TashkinDP , CelliBR , KestenS , LystigT , MehraS , DecramerM . Efficacy of tiotropium in men and women: 4‐year follow‐up in the uplift trial [Abstract]. Chest2009;136(4):24S‐h, 25. TashkinDP , DecramerM , CelliB , BurkhartD , CassinoC , KestenS . Baseline characteristics according to JOURder in a global respiratory trial [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:Poster #924. TroostersT , CelliB , KestenS , LiuD , MehraS , TashkinD , et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P3808]. [] TroostersT , CelliB , KestenS , LiuD , TashkinD , DecramerM . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial [Abstract]. Primary Care Respiratory Journal2010;19(2):A13 [49]. TroostersT , CelliB , LystigT , KestenS , MehraS , TashkinDP , et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. European Respiratory Journal2010;36(1):65‐73. TroostersT , KestenS , BurkhartD , CelliB , LiuD , MehraS , et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT Trial [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A2467. ZanioloO , IannazzoS , PradelliL , MiravitllesM . Pharmacoeconomic evaluation of tiotropium bromide in the long‐term treatment of chronic obstructive pulmonary disease (COPD) in Italy. European Journal of Health Economics2012;13(1):71‐80. ">Tashkin 2008a [UPLIFT]</a>; </p> <p><a href="./references#CD010844-bbs2-0061" title="DohertyD , TashkinD , KerwinE , Eduardo Matiz‐BuenoC , ShekarT , BanerjeeS , et al. Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26‐week trials [Abstract]. Chest2011;140(4):535A. KerwinE , TashkinD , Matiz‐BuenoCE , DohertyD , ShekarT , BanerjeeS , et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2011;140(4):558A. Matiz‐BuenoCE , DohertyD , KerwinE , TashkinD , ShekarT , BanerjeeS , et al. The long‐term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1‐year multicenter clinical trials [Abstract]. Chest2011;140(4):548A. TashkinD , DohertyD , KerwinE , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. The effect of mometasone furoate/formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest2011;140(4):549A. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed‐dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52‐week placebo‐controlled trials. International Journal of Chronic Obstructive Pulmonary Disease2012;7:73‐86. TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; <a href="./references#CD010844-bbs2-0062" title="ToY , NishimuraM , FukuchiY , KitawakiT , OkinoN , LassenC , et al. Long‐term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52‐week open‐labeled study [Abstract]. Respirology (Carlton, Vic.)2011;16(Suppl 2):96 [240]. ">To 2011</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0063" title="TonneiAB , BravoML , BrunM , TonnelAB . Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [Abstract]. American Thoracic Society International Conference; May 20‐25; San Diego. 2005:[B93] [Poster: 302]. TonneiAB , PerezT , GrosboisJM , BravoML , BrunM , TonnelAB . Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1934. TonnelAB , PerezT , GrosboisJM , VerkindreC , BravoML , BrunM . Effect of tiotropium on health‐related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease2008;3(2):301‐10. ">Tonnel 2008 [TIPHON]</a>; <a href="./references#CD010844-bbs2-0064" title="SciurbaFC , SiafakasN , TroostersT , KliozeSS , SutradharS , WeismanI , et al. The efficacy and safety of tiotropium handihaler, 18 µg, once daily plus PRN salbutamol versus placebo plus PRN salbutamol in COPD subjects naive to maintenance therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183(Meeting Abstracts):A1589. ">Trooster 2011</a>; <a href="./references#CD010844-bbs2-0065" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJ , HoogstedenHC , PrinsJB . Inhaled fluticasone propionate (FP) reduces the number of inflammatory cells in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A798. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , MulderPGH , BogaardJM , HoogstedenHC . Inhaled fluticasone propionate (FP) has a significant effect on FEV1 of COPD patients with bronchial hyperresponsiveness (BHR). American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A799. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxyJOUR species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a><sup>a</sup>; </p> <p><a href="./references#CD010844-bbs2-0066" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger2000;162(4):493‐7. ">Vestbo 1999</a>; <a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a><sup>a</sup>; <a href="./references#CD010844-bbs2-0070" title="GlaxoSmithKline . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500 µg BD, compared with placebo via Accuhaler, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com (accessed 6 March 2014). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2006;130(4 Suppl):182s. ZhengJP , YangL , WuYM , ChenP , WenZG , HuangWJ , et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest2007;132(6):1756‐63. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50 µg/fluticasone propionate 500 µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology (Carlton, Vic.)2006;11(Suppl 5):A150 [PS‐3‐9]. ">Zheng 2006</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Studies not contributing data to either outcome. </p> <p>bid = twice daily.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid combination therapy. </p> <p>LAMA = long‐acting muscarinic antagonist.</p> <p>PBO = placebo inhaler.</p> <p>qd = once daily.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Distribution of studies by individual treatment node</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis—blinding</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Arm removed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Analyses affected</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0008" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147 [P192]. BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):509s [2810]. BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148 [P193]. BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the Shine study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. WelteT , BarnesN , NagaseT , GallagherN , GreenY , HortonR , et al. QVA149 once daily is safe and well tolerated in patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A1478. WelteT , GallagherN , GreenY , HenleyM , BanerjiD . Dual bronchodilation with once‐daily QVA149 provides significantly improved clinical outcomes versus mono‐bronchodilator therapy: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4272. ">Bateman 2013 [SHINE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0025" title="BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4358]. BarnesPJ , PocockSJ , MagnussenH , IqbalA , KramerB , HigginsM , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics2010;23(3):165‐71. BarnesPJ , PocockSJ , MagnussenH , IqbalA , LawrenceD , KramerB , et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design [Abstract]. American Thoracic Society International conference, May 15‐20, San Diego. 2009:A4543 [Poster #J53]. ChapmanKR , RennardSI , DograA , OwenR , LassenC , KramerB . Long‐term safety and efficacy of indacaterol, a long‐acting beta2‐agonist, in subjects with COPD: a randomized, placebo‐controlled study. Chest2011;140(1):68‐75. DonohueJF , FogartyC , LotvallJ , MahlerDA , WorthH , YorganciogluA , et al. Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine2010;182(2):155‐62. FogartyC , HebertJ , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily provides effective 24‐h bronchodilation in COPD patients: a 26‐week evaluation vs placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2025]. FogartyC , WorthH , HerbertJ , IqbalA , OwenR , HigginsM , et al. Sustained 24‐h bronchodilation with indacaterol once‐daily in COPD: a 26‐week efficacy and safety study [Abstract]. American Thoracic Society International Conference; May 15‐20 San Diego. 2009:A4547 [Poster #J57]. JonesPW , MahlerDA , GaleR , OwenR , KramerB . Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine2011;105(6):892‐9. LotvallJ , CosioBG , IqbalA , SwalesJ , OwenR , KramerB , et al. Indacaterol once‐daily improves day and night‐time symptom control in COPD patients: a 26‐week study versus placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2029]. MahlerD , PalangeP , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves dyspnoea in COPD patients: a 26‐week placebo‐controlled study with open‐label tiotropium comparison [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[E4360]. RennardS , BantjeT , CentanniS , ChanezP , ChuchalinA , D'UrzoA , et al. A dose‐ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine2008;102(7):1033‐44. RennardSI , ChapmanKR , LuthraA , SwalesJ , LassenC , OwenR , et al. Once‐daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. Chest2009;136(4):4S‐f. WorthH , KleerupE , IqbalA , OwenR , KramerB , HigginsM . Safety and tolerability of indacaterol once‐daily in COPD patients versus placebo and tiotropium: a 26‐week study [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2030]. YorganciogluA , MahlerD , IqbalA , OwenR , HigginsM , KramerB . Indacaterol once‐daily improves health‐related quality of life in COPD patients: a 26 ‐week comparison with placebo and tiotropium [Abstract]. European Respiratory Society 19th Annual Congress; Sep 12‐15; Vienna. 2009:[P2028]. ">Donohue 2010 [INHANCE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0032" title="KerwinEM , HebertJ , PedinoffA , GallagherN , MartinC , BanerjiD . NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2920. KerwinEM , PedinoffA , CasaleTB , GallagherN , MartinC , BanerjiD . NVA237 once daily reduces COPD exacerbations with similar rates to tiotropium: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2255. KorenblatPE , HebertJ , GallagherN , MartinC , BanerjiD , LuY . NVA237 once daily improves dyspnea and health‐related quality of life in patients with COPD: the GLOW2 trial [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185(Meeting Abstracts):A2254. ">GLOW2 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m, SGRQ12m, FEV12m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0057" title="DecramerM , WedzichaJA , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Once‐daily QVA149 improves health‐related quality of life in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A4257. DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A1479. WedzichaJA , DecramerM , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , et al. Dual bronchodilation with QVA149 reduces COPD exacerbations: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2428. WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A2429. WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandstromT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. The Lancet Respiratory Medicine2013;1(3):199‐209. ">SPARK 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole study (2 arms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGRQ6m, FEV6m, SGRQ12m, FEV12m</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010844-bbs2-0067" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiotropium 18 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not appear in analyses</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>FEV = forced expiratory volume in one second</p> <p>SGRQ = St George's Respiratory Questionnaire</p> <p>6m = six month analysis</p> <p>12m = 12 month analysis</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis—blinding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">SGRQ class effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Sensitivity analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.70 to ‐2.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.66 to ‐3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.53 to ‐1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.58 to ‐2.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.18 to ‐1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.93 to ‐1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.06 to ‐0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.99 to ‐0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>SGRQ = St George's Respiratory Questionnaire.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">SGRQ class effects versus placebo (six months)a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">SGRQ individual treatment effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Rank (from class NWMA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> NWMA no class</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank (from class NWMA)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment (number daily doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form 12 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.60 to ‐0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.10 to ‐0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(10 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 300 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.63 to ‐1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.86 to ‐1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 150 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.95 to ‐1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.76 to ‐2.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm 50 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.98 to ‐1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.27 to ‐1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(7 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 5 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.16 to ‐1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.20 to ‐1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 18 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.12 to ‐1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.33 to ‐1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 200 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.04 to ‐1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐6.14 to ‐1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.40 to ‐1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐6.94 to ‐2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gly 50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.42 to ‐1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.74 to ‐1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.82 to ‐0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐2.32 to 0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(7 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut 500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.07 to ‐0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.40 to ‐0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(6 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mom 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐3.51 to ‐1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.47 to ‐1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/160 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.91 to ‐3.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.99 to ‐2.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/320 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.63 to ‐2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.39 to ‐2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐mom 12/200 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.82 to ‐2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐5.17 to ‐1.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐mom 12/400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.72 to ‐2.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.81 to ‐1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm‐flut 50/500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐4.97 to ‐3.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐5.60 to ‐3.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>SGRQ = St George's Respiratory Questionnaire.</p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">SGRQ individual treatment effects versus placebo (six months)a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">FEV1 class effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Sensitivity analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(100.60 to 164.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(98.93 to 165.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(81.78,124.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(79.01 to 126.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(71.98,127.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(70.41 to 130.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(33.06,96.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(31.23 to 97.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">FEV1 class effects versus placebo (six months)a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010844-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">FEV1 individual treatment effects versus placebo (six months)a </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> Class NWMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Effect vs placebo<br/> NWMA no class</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Rank (from class NWMA)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment (number daily doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CrI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pr (best)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form 12 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(60.70 to 122.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(13.00 to 94.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 300 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(71.95 to 150.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(63.69 to 209.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ind 150 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(72.32 to 127.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(65.74 to 133.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm 50 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(73.39 to 130.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(75.96 to 149.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>LAMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 5 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(81.87 to 131.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(73.82 to 145.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 10 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(79.80 to 142.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(62.88 to 175.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tio 18 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(85.54 to 125.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(82.93 to 129.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 200 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(59.06 to 123.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(9.47 to 107.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(5 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 200 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(65.20 to 127.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(11.81 to 134.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(4 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acl 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(80.93 to 143.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(45.06 to 168.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(2 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gly 50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(79.83 to 127.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(67.86 to 133.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(3 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud 400 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(23.86 to 94.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐29.22 to 58.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(14 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud 750+ (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(14.75 to 99.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(‐95.77 to 91.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(12 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut 250 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(34.19 to 101.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(29.36 to 122.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(11 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut 500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(40.20 to 109.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(54.90 to 138.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(8 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>LABA/ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/160 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(91.65 to 164.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(26.99 to 132.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Form‐bud 12/320 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(85.14 to 159.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(28.75 to 116.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm‐flut 50/250 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(106.20 to 182.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(116.20 to 226.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salm‐flut 50/500 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(104.40 to 172.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(104.10 to 197.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>For effects versus placebo, bigger values indicate larger benefits of the active treatment; all doses are given in micrograms. </p> <p>Crl = credible interval.</p> <p>FEV<sub>1</sub> = forced expiratory volume in one second. </p> <p>ICS = inhaled corticosteroid.</p> <p>LABA = long‐acting beta<sub>2</sub>‐agonist. </p> <p>LABA/ICS = long‐acting beta<sub>2</sub>‐agonist/inhaled corticosteroid. </p> <p>LAMA = long‐acting antimuscarinic antagonist.</p> <p>NWMA = network meta‐analysis.</p> <p>Pr = probability.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">FEV1 individual treatment effects versus placebo (six months)a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010844.pub2/full#CD010844-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010844.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010844-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010844-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010844-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010844-note-0001">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010844\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010844\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010844\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010844\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010844\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010844.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010844.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010844.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010844.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010844.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717632906"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010844.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717632910"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010844.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbc9e7eb99371',t:'MTc0MDcxNzYzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 